日本臨牀　74/増刊9　高尿酸血症・低尿酸血症

出版社： 日本臨牀社
発行日： 2016-11-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 高尿酸血症・低尿酸血症―最近の診断と治療―
電子書籍版： 2016-11-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,750 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,750 円(税込)

購入する

目次

  • 日本臨牀　74/増刊9　高尿酸血症・低尿酸血症

    ―目次―

    特集　高尿酸血症・低尿酸血症―最近の診断と治療―

    I　総論
    　1．高尿酸血症・痛風の治療ガイドライン（第2版）
    　2．高尿酸血症の疫学
    　3．高尿酸血症概論
    　4．高尿酸血症の性差
    　5．痛風関節炎の発症機序
    　
    II　プリン・尿酸代謝の基礎
    　1．プリン代謝経路と尿酸産生
    　2．GC/MS−尿メタボローム解析による
    　　　プリン代謝異常症の早期診断
    　3．尿酸排泄機構
    　4．尿酸酸化酵素（ウリカーゼ）と種差
    　　　―高尿酸値は長寿と知性の証―
    　5．尿酸トランスポーター機能評価法
    　6．尿酸の抗酸化作用
    　7．尿酸とホルモン

    III　高尿酸血症の臨床
    　1．高尿酸血症の病型分類
    　2．高尿酸血症の疫学病理・病態
    　3．高尿酸血症・痛風の検査・診断・治療
    　4．高尿酸血症関連疾患とその管理
    　5．痛風関節炎と類縁疾患の鑑別診断

    IV　低尿酸血症の臨床
    　1．低尿酸血症の定義と疫学
    　2．低尿酸血症の分子機序
    　3．低尿酸血症の臨床的意義
    　4．低尿酸血症の管理

    V　特論
    　1．尿酸とレニン・アンジオテンシン系
    　2．痛風発作の季節性
    　3．SGLT2阻害薬による尿酸排泄機序
    　4．IL-6の尿酸排泄機序
    　5．小児期および思春期に発症した痛風の全国調査
    　6．GWAS（ゲノムワイド関連解析）による高尿酸血症の研究課題

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第1版 (高尿酸血症・痛風の治療ガイドライン作成委員会編). 日本痛風・核酸代謝学会, 2002.
 
2) 高尿酸血症・痛風の治療ガイドライン 第2版 (高尿酸血症・痛風の治療ガイドライン作成委員会編), メディカルレビュー社, 2010.
 
3) 高尿酸血症・痛風の治療ガイドライン 第2版追補版 (高尿酸血症・痛風の治療ガイドライン作成委員会編), メディカルレビュー社, 2012.
 
4) Zhang W, et al ; EULAR Standing Committee for International Clinical Studies Including Therapeutics : EULAR evidence based recommendations for gout. Part II ; Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 : 1312-1324, 2006.
PubMed
5) Khanna D, et al ; American College of Rheumatology : 2012 American College of Rheumatology guidelines for management of gout. Part 1 : systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64 (10) : 1431-1446, 2012.
PubMed
P.16 掲載の参考文献
1) 箱田雅之 : 高尿酸血症・痛風の疫学. 綜合臨牀 59 : 195-200, 2010.
Medical*Online
2) 厚生労働省 : 平成26年国民健康・栄養調査結果の概要, 2015.
 
3) 冨田眞佐子, 水野正一 : 高尿酸血症は増加しているか? -性差を中心に. 痛風と核酸代謝 30 : 1-5, 2006.
 
4) 箱田雅之, 冨田眞佐子 : 高尿酸血症の年齢差の原因-診療報酬明細書 (レセプト) データベースを利用した解析. 痛風と核酸代謝 37 : 111-116, 2013.
 
5) Oyama C, et al : Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med 209 : 257-262, 2006.
PubMed
6) Hongo M, et al : Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J 74 : 1570-1577, 2010.
PubMed
7) 川崎拓, 七川歓次 : 住民調査による痛風の疫学調査. 痛風と核酸代謝 30 : 66, 2006.
 
8) Campion EW, et al : Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82 (3) : 421-426, 1987.
PubMed
9) Lin KC, et al : Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 27 (4) : 1045-1050, 2000.
PubMed
10) 市田公美ほか : 無症候性高尿酸血症の予後に関する研究-II. 尿酸 10 : 40-44, 1986.
 
11) 国民生活基礎調査 (厚生労働省大臣官房統計情報部編), 2015.
 
12) Kuo CF, et al : Rising burden of gout in the UK but continuing suboptimal management : a nationwide population study. Ann Rheum Dis 74 : 661-667, 2015.
PubMed
13) 加藤玲奈ほか : 小児期及び思春期に発症した痛風に関する全国調査. 痛風と核酸代謝 38 : 43-48, 2014.
 
14) 大澤彦太ほか : 高齢発症痛風の臨床的特徴. 痛風と核酸代謝 39 : 102, 2015.
 
P.21 掲載の参考文献
1) Johnson RJ, Rideout BA : Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med 350 : 1071-1073, 2004.
PubMed
2) Fam AG : Gout : excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet. J Rheumatol 32 : 773-777, 2005.
 
3) http://www.mhlw.go.jp/stf/houdou/2r9852000002q1st.html
 
4) Johnson RJ, et al : Lessons from comparative physiology : could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B 179 : 67-76, 2009.
PubMed
5) Whitfield JB, Martin NG : Inheritance and alcohol as factors influencing plasma uric acid levels. Acta Genet Med Gemellol (Roma) 32 : 117-126, 1983.
PubMed
6) Emmerson BT, et al : Genetic control of the renal clearance of urate : a study of twins. Ann Rheum Dis 51 : 375-377, 1992.
PubMed
7) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
8) Ozaki K, et al : Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32 : 650-654, 2002.
PubMed
9) Kottgen A, et al : Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 45 : 145-154, 2013.
PubMed
10) Gustafsson D, Unwin R : The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol 14 : 164, 2013.
PubMed
11) Qiu L, et al : Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 13 : 664, 2013.
PubMed
12) Chang J, et al : Hyperuricemia after exposure to polychlorinated dibenzo-p-dio) dns and dibenzofurans near a highly contaminated area. Epidemiology 24 : 582-589, 2013.
 
13) Lee YM, et al : Persistent organic pollutants and hyperuricemia in the U. S. general population. Atherosclerosis 230 : 1-5, 2013.
 
14) Dalbeth N, Stamp L : Hyperuricaemia and gout : time for a new staging system? Ann Rheum Dis 73 : 1598-1600, 2014.
PubMed
15) Perez-Ruiz F, et al : Hyperuricaemia with deposition : latest evidence and therapeutic approach. Ther Adv Musculoskelet Dis 7 : 225-233, 2015.
PubMed
16) Maueroder C, et al : How neutrophil extracellular traps orchestrate the local immune response in gout. J Mol Med (Berl) 93 : 727-734, 2015.
 
17) Andres M, et al : Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia : An Exploratory Study. Arthritis Rheumatol 68 : 1531-1539, 2016.
PubMed
18) Larsen KS, et al : Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study. Arthritis Res Ther 17 : 304, 2015.
PubMed
19) Sluijs I, et al : A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes 64 : 3028-3036, 2015.
PubMed
20) White J, et al : Plasma urate concentration and risk of coronary heart disease : aMendelian randomisation analysis. Lancet Diabetes Endocrinol 4 : 327-336, 2016.
 
21) Chen JH, et al : Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout : A Case-Matched Cohort Study. PLoS One 10 : e0145193, 2015.
 
22) Lane NE, et al : Association of serum uric acid and incident nonspine fractures in elderly men : the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 29 : 1701-1707, 2014.
PubMed
23) Bardin T, Richette P : Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 26 : 186-191, 2014.
PubMed
24) Chen JH, et al : Gender-spechic risk factors for incident gout : a prospective cohort study. Clin Rheumatol 31 : 239-245, 2012.
 
P.29 掲載の参考文献
1) Mikkelsen WM, et al : The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia : Tecumseh, Michigan 1959-1960. Am J Med 39 : 242-251, 1965.
PubMed
2) Akizuki S : Serum uric acid levels among thirty-four thousand people in Japan. Ann Rheum Dis 41 : 272-274, 1982.
PubMed
3) Darlington LG, et al : Changes in urate metabolism after castration of patients suffering from carcinoma of the prostate. Adv Exp Med Biol 309A : 235-238, 1991.
PubMed
4) Nishiyama T, et al : The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90 : 657-660, 2005.
 
5) Hosoyamada M, et al : The effect of testosterone upon the urate reabsorptive transport system in mouse kidney. Nucleosides Nucleotides Nucleic Acids 29 : 574-579, 2010.
PubMed
6) Gopal E, et al : Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney. Biochim Biophys Acta 1768 : 2690-2697, 2007.
PubMed
7) Li T, et al : Molecular cloning and characterization of a human urate transporter (hURAT1) gene promoter. Biochim Biophys Acta 1681 : 53-58, 2004.
PubMed
8) Trevoux R et al : Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 8 : 309-326, 1986.
PubMed
9) Adamopoulos D, et al : The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh) 85 : 198-208, 1977.
PubMed
10) Kailajarvi M, et al : Early effects of adjuvant tamoxifen therapy on serum homlones, proteins and lipids. Anticancer Res 20 : 1323-1327, 2000.
 
11) Atallah AN, et al : Progesterone increases glomerular filration rate, urinary kallikrein excretion and uric acid clearance in normal women. Braz J Med Biol Res 21 : 71-74, 1988.
 
12) Boyle JA, et al : Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy. J Clin Pathol 19 : 501-503, 1966.
 
13) Takiue Y, et al : The effect of female hormones upon urate transport systems in the mouse kidney. Nucleosides Nucleotides Nucleic Acids 30 : 113-119, 2011.
PubMed
14) Zeng M, et al : Estrogen receptor beta signaling induces autophagy and downregulates Glut9 expression. Nucleosides Nucleotides Nucleic Acids 33 : 455-465, 2014.
PubMed
15) Doring A, et al : SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40 : 430-436, 2008.
PubMed
P.35 掲載の参考文献
1) Takeuchi O, et al : Pattern recognition receptors and inflammation. Cell 140 : 805-820, 2010.
PubMed
2) Strowig T, et al : Inflammasomes in health and disease. Nature 481 : 278-286, 2012.
PubMed
3) Lamkanfi M, et al : Mechanisms and functions of inflammasomes. Cell 157 : 1013-1022, 2014.
PubMed
4) Misawa T, et al : Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 14 : 454-460, 2013.
PubMed
5) Zhou R, et al : A role for mitochondria in NLRP3 inflammasome activation. Nature 469 : 221-225, 2011.
 
6) Howard J, et al : Dynamics and mechanics of the microtubule plus end. Nature 422 : 753-758, 2003.
PubMed
7) Firestone AJ, et al : Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature 484 : 125-129, 2012.
PubMed
8) Wloga D, et al : Post-translational modifications of microtubules. J Cell Sci 123 : 3447-3455, 2010.
PubMed
9) Friedman JR et al : ER sliding dynamics and ER-mitochondrial contacts occur on acetylated microtubules. J Cell Biol 190 : 363-375, 2010.
PubMed
10) Akella JS, et al : MEC-17 is an alpha-tubulin acetyltransferase. Nature 467 : 218-222, 2010.
PubMed
11) North BJ, et al : The human Sir 2 ortholog, SIRT2, is an NAD+ -dependent tubulin deacetylase. Mol Cell 11 : 437-444, 2003.
 
12) Naik E, et al : Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 208 : 417-420, 2011.
PubMed
13) Misawa T, et al : Resveratrol inhibits the acetylated α-tubulin-mediated assembly of the NLRP3-inflammasome. Int Immunol 27 : 425-434, 2015.
 
14) Youm YH, et al : The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21 : 263-269, 2015.
 
15) Coll RC, et al : A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21 : 248-255, 2015.
PubMed

II プリン・尿酸代謝の基礎

P.44 掲載の参考文献
1) The Online Metabolic & Molecular Bases of Inherited Disease (ed by Valle D, et al), McGraw-Hill, New York, 2010.
 
2) Fu R, et al : Genotype-phenotype correlations in neurogenetics : Lesch-Nyhan disease as a model disorder. Brain 137 (Pt 5) : 1282-1303, 2014.
 
3) Becker MA, et al : The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest 96 : 2133-2141, 1995.
PubMed
4) Ichida K, et al : Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest 99 : 2391-2397, 1997.
PubMed
5) de Brouwer AP, et al : PRPS1 mutations : four distinct syndromes and potential treatment. Am J Hum Genet 86 : 506-518, 2010.
PubMed
6) Ogasawara N, et al : Molecular analysis of a female Lesch-Nyhan patient. J Clin Invest 4 : 1024-1027, 1989.
 
7) Mitchell BS, Kelley WN : Purinogenic immunodeficiency diseases : clinical features and molecular mechanisms. Ann Intern Med 92 : 826-831, 1980.
PubMed
8) Cheung KJ, et al : Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5 : 115-128, 2007.
PubMed
9) Choi HK, et al : Alcohol intake and risk of incident gout in men : a prospective study. Lancet 363 : 1277-1281, 2004.
 
P.50 掲載の参考文献
1) Trethewey RN, et al : Metabolic profiling : a Rosetta Stone for genomics? Curr Opin Plant Biol 2 : 83-85, 1999.
PubMed
2) Schnackenberg LK, Beger RD : Monitoring the health to disease continuum With global metabolic profiling and systems biology. Pharmacogenomics 7 : 1077-1086, 2006.
PubMed
3) Matsumoto L Kuhara T : A new chemical diagnostic method for inborn errors of metabolism by mass spectrometry-rapid, practical, and simultaneous urinary metabolites analysis. Mass Spectrom Rev 15 : 43-57, 1996.
 
4) Kuhara T : Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 781 : 497-517, 2002.
PubMed
5) Kuhara T : Gas chromatographic-mass spectrometric urinary metabolome analysis to study mutations of inborn errors of metabolism. Mass Spectrom Rev 24 : 814-827, 2005.
PubMed
6) Suzuki K, et al : Family study of 2, 8-dihydroxyadenine stone formation : report of two cases of a compound heterozygote fOr adenine phosphoribosyltransferase deficiency (APRT*J/APRT*Q0). Int J Urol 4 : 304-306, 1997.
PubMed
7) Kimura T, et al : Quiz page June 2009 : Worsening kidney function with a history of urolithiasis. Am J Kidney Dis 53 : A37-39, 2009.
PubMed
8) Ohdoi C, et al : Chemical diagnosis of Lesch-Nyhan syndrome using gas chromatography-mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci 792 : 123-130, 2003.
PubMed
9) Takayama T, et al : Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. Clin Genet 86 : 342-348, 2014.
PubMed
10) Yamanouchi M, et al : Calcified nodules on fingers in primary hyperoxaluria type 2. Lancet Diabetes Endocrinol 4 : 468, 2016.
PubMed
11) Ito T, et al : Rapid Screening of High-Risk Patients for Disorders of Purine and Pyrimidine Metabolism Using HPLC-Electrospray Tandem Mass Spectrometry of Liquid Urine or Urine-soaked Filter Paper Strips. Clin Chem 50 : 2117-2124, 2004.
 
12) 久原とみ子 : メタボローム解析. 高尿酸血症と痛風 23 : 37-42, 2015.
Medical*Online
13) Ceballos-Picot I, et al : 2, 8-Dihydroxyadenine urolithiasis : a not so rare inborn error of purine metabolism. Nucleosides Nucleotides Nucleic Acids 33 : 241-252, 2014.
 
14) Zaidan M, et al : Recurrent 2, 8-dihydroxyadenine nephropathy : a rare but preventable cause of renal allograft failure. Am J Transplant 14 : 2623-2632, 2014.
PubMed
15) Bollee G, et al : Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis 2 : 31-43, 2015.
PubMed
P.54 掲載の参考文献
1) Anzai N, et al : Recent advances in renal urate transport : characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16 : 89-95, 2012.
PubMed
2) 安西尚彦ほか : 尿酸関連トランスポーターとその異常. 内分泌・糖尿病・代謝内科 43 : 8-12, 2016.
 
3) Anzai N, Endou H : Chapter 4 Renal basis of hyperuricemia. In : Gout and Crystal Arthropathies (ed by Terkeltaub R), 1st ed, p 51-58, Elsevier Saunders, Philadelphia, 2012.
 
4) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
5) Kamatani Y, et al : Genome-Wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 42 : 210-215, 2010.
 
6) 安西尚彦ほか : 新規尿酸トランスポーターと腎尿酸輸送の分子機構Annual Review 腎臓 2014 (富野康日己ほか編), p28-34, 中外医学社, 2014.
 
7) Kolz M, et al : Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5 : e1000504, 2009.
PubMed
8) Li S, et al : The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 3 : e194, 2007.
PubMed
9) Vitart V, et al : SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40 : 437-442, 2008.
PubMed
10) Anzai N, et al : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283 : 26834-26838, 2008.
PubMed
11) Augustin R, et al : Identification and characterization of human glucose transporter-like protein 9 (GLUT9) : alternative splicing alters trafficking. J Biol Chem 279 : 16229-16236, 2004.
PubMed
12) Matsuo H, et al : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83 : 744-751, 2008.
PubMed
13) Dehghan A, et al : Association of three genetic loci with uric acid concentration and risk of gout : a genome-wide association study. Lancet 372 : 1953-1961, 2008.
 
14) Jutabha P, et al : Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 285 : 35123-35132, 2010.
PubMed
15) Woodward OM, et al : Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 106 : 10338-10342, 2009.
PubMed
16) Togawa N, et al : A Na+ -phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol 302 : C1652-C1660, 2012.
PubMed
P.63 掲載の参考文献
1) Friedman TB, et al : On the loss of uricolytic activity during primate evolution-I. Silencing of urate oxidase in a hominoid ancestor. Comp Biochem Physiol B 81 : 653-659, 1985.
 
2) 滝上裕一ほか : 尿酸排泄動態の種差. 高尿酸血症と痛風 17 : 16-20, 2009.
Medical*Online
3) Sato K et al : Identification of human urinary stains by the quotient uric acid/urea nitrogen. Forensic Sci Int 45 : 27-38, 1990.
PubMed
4) 藤城雅也ほか : 尿酸/クレアチニン比とHPLCクロマトグラムを指標とするヒト尿斑証明法. 昭和医学会雑誌 68 : 175-181, 2008.
 
5) 古田聰ほか : 霊長類尿斑の人獣鑑別. 犯罪学雑誌 67 : 237-242, 2001.
 
6) 高橋良治ほか : 尿酸/尿素窒素比を指標とするヒト尿斑証明法の検討 III. 尿酸吸収極大の減少率を指標とするウリカーゼ法との比較. 昭和医学会雑誌 69 : 295-304, 2009.
 
7) Christen P, et al : Urate oxidase in primate phylogenesis. Eur J Biochem 12 : 3-5, 1970.
PubMed
8) 大多和威行ほか : 血漿中アラントイン/尿酸比からみた霊長類のプリン代謝に関する研究. 昭和医学会雑誌 70 : 263-271, 2010.
 
9) 京都大学霊長類研究所 : 新しい霊長類学 人を深く知るための100問100答, 講談社, 2009.
 
10) Zihlman AL (木村邦彦監訳) : カラースケッチ-ヒトの進化, 廣川書店, 1987.
 
11) Cutler RG : Antioxidants and aging. Am J Clin Nutr 53 : 373S-379S, 1991.
PubMed
12) Johnson RJ, et al : The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 71 : 22-31, 2008.
PubMed
13) Wikipedia : フサオマキザル. [https://ja.wikipedia.org/wiki/%E3%83%95%E3%82%B5%E3%82%AA%E3%83%9E%E3%82%AD%E3%82%B6%E3%83%AB (accessed May 2, 2016)]
 
14) Moura AC : Stone banging by wild capuchin monkeys : an unusual auditory display. Folia Primatol (Basel) 78 : 36-45, 2007.
PubMed
15) Anderson JR, et al : Capuchin monkeys judge third-party reciprocity. Cognition 127 : 140-146, 2013.
PubMed
P.67 掲載の参考文献
1) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
2) Sekine T, et al : Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272 : 18526-18529, 1997.
PubMed
3) Witkowska K et al : Human SLC2A9 a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol 303 : F527-539, 2012.
PubMed
4) Anzai N, et al : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283 : 26834-26838, 2008.
PubMed
5) Woodward OM, et al : Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 106 : 10338-10342, 2009.
PubMed
6) Shin HJ, et al : Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology 16 : 156-162, 2011.
PubMed
7) Sato M, et al : Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25 : 639-646, 2008.
PubMed
8) Van Aubel RA, et al : Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288 : F327-333, 2005.
PubMed
9) Murer H, Gmaj P : Transport studies in plasma membrane vesicles isolated from renal cortex. Kidney Int 30 : 171-186, 1986.
PubMed
10) Kondo C, et al : Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21 : 1895-1903, 2004.
PubMed
11) 堀了平, 乾賢一 : 細胞膜小胞による膜輸送実験法. 膜学実験法 (中垣正幸編), p155-169, 喜多見書房, 1984.
 
12) Matsuo H, et al : Common defects of ABCG2, a high-capacity urate exporter, cause gout : a function-based genetic analysis in a Japanese population. Sci Transl Med 1 : 5ra11, 2009.
 
13) Nakanishi T, et al : Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate. Nephrol Dial Transplant 28 : 603-611, 2013.
PubMed
14) Ichida K et al : Clinical and molecular analysis of patients with renal hypouricemia in Japan-Influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 : 164-173, 2004.
PubMed
15) Dinour D, et al : Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 21 : 64-72, 2010.
PubMed
P.73 掲載の参考文献
1) Babior BM : NADPH oxidase : an update. Blood 93 : 1464-1476, 1999.
PubMed
2) Heyworth PG, et al : Neutrofil NADPH oxidase assembly : translocation of p47phox and p67phox requires the interaction between p47phox and cytochrome b558. J Clin Invest 87 : 352-356, 1991.
 
3) Madamanchi NR, et al : Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25 : 29-38, 2005.
PubMed
4) Landmesser U, et al : Oxidation of tetrahydrobiopterin leads to uncoupling of endothelia1 cell nitric oxide synthase in hypertension. J Clin Invest l 11 : 1201-1209, 2003.
 
5) Spiekermann S, et al : Electron spin resonance characterization of vascular xanthine and NAD (P) H oxidase activity I patients with coronary artery disease : relation to endothelium-dependent vasodilation. Circulation 107 : 1383-1389, 2003.
PubMed
6) Chakraborti T, et al : Oxidant, mitochondria, and calcium : an overview. Cell Signal 11 : 77-85, 1999.
PubMed
7) Ames BN, et al : Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer : a hypothesis. Proc Natl Acad Sci USA 78 : 6858-6862, 1981.
PubMed
8) Kuzkaya N, et al : Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols : implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 : 22546-22554, 2003.
PubMed
9) Kuzkaya N, et al : Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols : implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 70 : 343-354, 2005.
PubMed
10) Skinner KA, et al : Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 273 : 24491-24497, 1998.
PubMed
11) Squadrito GL, et al : Reaction of uric acid with peroxynitrite and impncations for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376 : 333-337, 2000.
PubMed
12) Davies KJ, et al : Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235 : 747-754, 1986.
PubMed
13) Hink HU, et al : Peroxidase properties of extracellular superoxide dismutase : role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 22 : 1402-1408, 2002.
PubMed
14) Sautin YY, et al : Adverse ef｛iects of the classic antioxidant uric acid in adipocytes : NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293 : C584-596, 2007.
 
P.76 掲載の参考文献
1) Engeli S, et al : The adipose-tissue renin-angiotensin-aldosterone system : Role in the metabolic syndrome? Int J Biochem Cell Biol 35 : 807-825, 2003.
PubMed
2) Janke J, et al : Mature adipocytes inhibit in vitro differentiation of human preadipocytes Via angiotensin type 1 receptors. Diabetes 51 : 1699-1707, 2002.
PubMed
3) Goossens GH, et al : Endocrine role of the renin-angiotensin system in human adipose tissue and muscle : effect ofβ-adrenergic stimulation. Hypertension 49 : 542-547, 2007.
 
4) Corry DB, et al : Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26 : 269-275, 2008.
PubMed
5) Mazzah M, et al : Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38 : 1101-1106, 2013.
 
6) Zhang J, et al : Elevated serum uric acid is associated with angiotensinogen in obese patients with untreated hypertension. J Clin Hypertens 16 : 569-574, 2014.
 
7) Feig DI, et al : Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension : a randomized trial. JAMA 300 : 924-932, 2008.
PubMed
8) 奈良枝里子ほか : レニン・アンジオテンシン・アルドステロンと尿酸. 高尿酸血症と痛風 22 : 47-52, 2014.
Medical*Online
9) 南場雅章ほか : 原発性アルドステロン症患者における尿酸代謝の検討. 日本内分泌学会雑誌 68 : 51-61, 1992.
Medical*Online
10) Verdecchia P, et al : Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36 : 1072-1078, 2000.
PubMed
11) Alderman MH, et al : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34 : 144-150, 1999.
PubMed
12) Goicoechea M, et al : Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 : 1388-1393, 2010.
PubMed
13) Heieggen A, et al : The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 : 1041-1049, 2004.
PubMed
14) Athyros VG, et al ; GREACE Study Collaborative Group : Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease ; a subgroup analysis of the GREek Atrovastatin and Coronary-heart disease Evaluation (GREACE) study. Am J Kidney Dis 43 : 589-599, 2004.
 
15) Saito J, et al : The alkalizer citrate reduces serum uric acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 35 : 145-154, 2010.
PubMed
P.81 掲載の参考文献
1) Shinosaki T, et al : Circadian rhythm of plasma uric acid and handling stress-induced hyperuricemia in conscious cebus monkeys. JPn J pharmacol 58 : 443-450, 1992.
PubMed
2) Puschel GP, et al : Increase of urate formation by stimulation of sympathetic hepatic nerves, circulating noradrenaline and glucagon in the perfused rat liver. FEBS Lett 219 : 145-150, 1987.
PubMed
3) 井野口卓ほか : 褐色細胞腫の病勢に伴い血清尿酸値の変動を認めた1例. 高尿酸血症と痛風 14 : 160-162, 2006.
Medical*Online
4) Yamamoto T, et al : Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol. Metabolism 50 : 1230-1233, 2001.
PubMed
5) Hisatome I, et al : Control of AMP deaminase 1 binding to myosin heavy chain. Am J Physiol 275 : C870-881, 1998.
PubMed
6) Mineo I, Tarui S : Myogenic hyperuricemia : what can we learn from metabolic myopathies? Muscle Nerve Suppl 3 : S75-81, 1995.
PubMed
7) Ohtahara A, et al : The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. J Hypertens 19 : 575-582, 2001.
 
8) 衣川徹ほか : 運動時プリン分解反応と血漿ノルエピネフリン反応. 痛風と核酸代謝 27 : 135-142, 2003.
 
9) Hamada T, et al : Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension. Clin Exp Hypertens 34 : 470-473, 2012.
PubMed
10) Mizuta E, et al : A vasodilating β1 blocker celiprolol inhibits muscular release of uric acid precursor in patients with essential hypertension. Horm Metab Res 45 : 69-73, 2013.
 
P.85 掲載の参考文献
1) Kuzell WC, et al : Some observations on 520 gouty patients. J Chronic Dis 2 : 645-669, 1955.
PubMed
2) Leeper RD, et al : Hyperuricemia in myxedema. J Clin Endocrinol Metab 20 : 1457-1466, 1960.
PubMed
3) Erickson AR, et al : The prevalence of hypothyroidism in gout. Am J Med 97 : 231-234, 1994.
 
4) Giordano N, et al : Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 19 : 661-665, 2001.
 
5) Saini V, et al : Correlation of creatinine with TSH levels in overt hypothyroidism-A requirement for monitoring of renal function in hypothyroid patients? Clin Biochem 45 : 212-214, 2012.
PubMed
6) Ford HC, et al : Renal function and electrolyte levels in hyperthyroidism : urinary protein excretion and the plasma concentrations of urea, creatinine, uric acid, hydrogen ion and electrolytes. Clin Endocrinol (Oxf) 30 : 293-301, 1989.
PubMed
7) Sato A, et al : Hyperuricemia in patients with hyperthyroidism due to Graves' disease. Metabolism 44 : 207-211, 1995.
PubMed
8) 内野卓也ほか : 当院における甲状腺ホルモンと血清尿酸値の関係の検討. 痛風と核酸代謝 39 : 43, 2015.
 
9) Katz AI, et al : Thyroid hormone and the kidney. Nephron 15 : 223-249, 1975.
PubMed
10) Montenegro J, et al : Changes in renal function in primary hypothyroidism. Am J Kidney Dis 27 : 195-198, 1996.
PubMed
11) Shirota T, et al : Alteration of renal function in hypenhyroidism : increased tubular secretion of creatinine and decreased distal tubular delivery of chloride. Metabolism 41 : 402-405, 1992.
PubMed
12) Raber W, et al : Serum uric acid concentration and thyroid-stimulating-hormone (TSH) : results of screening for hyperuricemia in 2359 consecutive patients with various degrees of thyroid dysfunction. Wien Min Wochenschr 111 : 326-328, 1999.
 
P.89 掲載の参考文献
1) Matsuura F, et al : Effect of visceral fat accumulation on uric acid metabolism in male obese subjects : visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47 (8) : 929-933, 1998.
PubMed
2) Hikita M, et al : Relationship between hyperuricemia and body fat distribution. Intern Med 46 : 1353-1358, 2007.
PubMed
3) Bonora E, et al : Prevalence of insulin resistance in metabolic disorders : the Bruneck Study. Diabetes 47 : 1643-1649, 1998.
PubMed
4) Quinones Galvan A, et al : Effect of insulin on uric acid excretion in humans. Am J Physiol 268 : E1-E5, 1995.
PubMed
5) Muscelli E, et al : Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9 : 746-752, 1996.
PubMed
6) Cohen JL, et al : Hyperuricemia in glycogen storage disease type I contributions by hypoglycemia and hyperglucagonomia to increased urate production. J Clin Invest 75 : 251-257, 1985.
PubMed
7) Roe TF, Kogut MD : The pathogenesis of hyperuricemia in glycogen storage disease, type I. Pediatr Res 11 : 664-669, 1977.
PubMed
8) Maire I, et al : Biochemical diagnosis of hepatic glycogen storage disease ; 20 years French experience. Clin Biochem 24 : 169-178, 1991.
PubMed
9) Talente GM, et al : Glycogen storage disease in adults. Ann Intern Med 120 : 218-226, 1994.
PubMed
10) 河野典夫ほか : グリコーゲン病 (糖原病). 日本臨牀 51 (増刊 : 本邦臨床統計集 (下)) : 285-296, 1993.
 
11) Lalanne M, Henderson JF : Effects of hormones and drugs on phosphoribosyl pyrophosphate concentrations in mouse liver. Can J Biochem 53 : 394-399, 1975.
PubMed
12) Itakura M, et al : In vivo inhibition of the rate of de novo purine synthesis in rat liver by glucagon. Metabolism 35 : 758-762, 1986.
PubMed
13) Yamamoto T, et al : Effect of glucagon on renal excretion of oxypurinol and purine bases. J Rheumatol 24 (4) : 708-713, 1997.
 
14) Yamamoto T, et al : Effect of bucladesine sodium on the plasma concentrations and urinary excretion of purine bases and uridine. Metabolism 47 (8) : 1005-1008, 1998.
PubMed
15) Yamamoto T, et al : Effect of octreotide acetate on the plasma concentration and urinary excretion of uridine and purine bases. Endocr J 49 (2) : 139-144, 2002.
PubMed
P.93 掲載の参考文献
1) Wenzel V, et al ; European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group : A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 350 (2) : 105-113, 2004.
 
2) Robben JH, et al : Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 291 (2) : F257-F270, 2006.
PubMed
3) Dorhout Mees EJ, et al : Elevation of uric aicd clearance caused by inappropriate antidiuretic hormone secretion. Acta Med Scand 189 (1-2) : 69-72, 1971.
 
4) 蔵城雅文 : 諸領域の疾患における高尿酸血症とその病態・治療 各種内分泌疾患の尿酸代謝への影響. 痛風と核酸代謝 36 (2) : 143, 2012.
 
5) Shichiri M, et al : Renal handling of urate in the syndrome of inappropriate secretion of antidiuretic hormone. Arch Intern Med 145 (11) : 2045-2047, 1985.
PubMed
6) Decaux G, Musch W : Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 3 (4) : 1175-1184, 2008.
PubMed
7) Decaux G, et al : Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia. Am J Med 103 (5) : 376-382, 1997.
PubMed
8) Decaux G, et al : Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol 7 (5) : 805-810, 1996.
 
9) Inomata T, et al : Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 25 (Suppl 1) : S57-S65, 2011.
 
10) Fukunami M, et al : Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics : a phase III open-label study. Cardiovasc Drugs Ther 25 (Suppl 1) : S47-S56, 2011.
 
11) Irazabal MV, et al : Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80 (3) : 295-301, 2011.
PubMed

III 高尿酸血症の臨床

P.101 掲載の参考文献
1) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
2) 高尿酸血症・痛風の治療ガイドライン, 第2版 (高尿酸血症・痛風の治療ガイドライン改訂委員会編), 日本痛風・核酸代謝学会発行, 2010.
 
3) Anzai N, et al : Recent advances in renal urate transport : characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16 : 89-95, 2012.
PubMed
4) Matsuo H, et al : Common defects of ABCG2, a high-capacity urate exporter, cause gout : a function-based genetic analysis in a Japanese population. Sci Transl Med 1 : 5ra11, 2009.
 
5) Matsuo H, et al : Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep 3 : 2014, 2013.
 
6) 松尾洋孝 : 痛風の原因遺伝子. Gout and Nucleic Acid Metabolism 34 : 159-169, 2010.
 
7) Goldfarb DS, et al : Febuxostat in gout : serum urate response in uric acid overproducers and underexcretors. J Rheumatol 38 : 1385-1389, 2011.
PubMed
8) Yamamoto T, et al : Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Mod Rheumatol 25 : 779-783, 2015.
PubMed
9) Perez-Ruiz F, et al : Renal underexcretion of uric acid is present in patients With apparent high urinary uric acid output. Arthritis Rheum 47 : 610-613, 2002.
PubMed
P.107 掲載の参考文献
1) Hui JY, et al : The independent association between parathyroid hormone levels and hyperuricemia : a national population study. Arthritis Res Ther 14 : R56, 2012.
PubMed
2) https://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/111pth_c_met.pdf
 
3) Whitfield JB, Martin NG : Inheritance and alcohol as factors influencing plasma uric acid levels. Acta Genet Med Gemellol (Roma) 32 : 117-126, 1983.
PubMed
4) Perez-Ruiz F, Becker MA : Inflammation : a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin 31 (Suppl 2) : 9-14, 2015.
 
5) Merriman TR : An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther 17 : 98, 2015.
PubMed
6) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
7) Kottgen A, et al : Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 45 : 145-154, 2013.
PubMed
8) Torralba KD, et al : The interplay between diet, urate transporters and the risk for gout and hyperuricemia : current and future directions. Int J Rheum Dis 15 : 499-506, 2012.
PubMed
9) Qiu L, et al : Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 13 : 664, 2013.
PubMed
10) Chang J, et al : Hyperuricemia after exposure to polychlorinated dibenzo-p-dioxins and dibenzofurans near a highly contaminated area. Epidemiology 24 : 582-589, 2013.
 
11) Lee YM, et al : Persistent organic pollutants and hyperuricemia in the US. general population. Atherosclerosis 230 : 1-5, 2013.
PubMed
12) Beavers KM, et al : Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels : Findings from NHANES III. J Nutr Health Aging 13 : 177-182, 2009.
 
13) de Oliveira EP, et al : Dietary, anthropometric, and biochemical detemlinants of uric acid in free-living adults. Nutr J 12 : 11, 2013.
PubMed
14) Deshmane SL, et al : Monocyte chemoattractant protein-1 (MCP-1) : an overview. J Interferon Cytokine Res 29 : 313-326, 2009.
PubMed
15) Xiao J, et al : Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med 35 : 1347-1354, 2015.
 
16) de Oliveira EP, Burini RC : High plasma uric acid concentration : causes and consequences. Diabetol Metab Syndr 4 : 12, 2012.
PubMed
17) Choi HK Curhan G : Beer, liquor, and wine consumption and serum uric acid level : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 51 : 1023-1029, 2004.
PubMed
18) Choi HK, et al : Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 52 : 283-289, 2005.
PubMed
19) Choi JW, et al : Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 59 : 109-116, 2008.
PubMed
20) Stamp LK, et al : Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout : a pilot randomized controlled trial. Arthritis Rheum 65 : 1636-1642, 2013.
 
21) Brandstatter A, et al : Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 31 : 1662-1667, 2008.
PubMed
22) Urano W, et al : Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 69 : 1232-1234, 2010.
PubMed
23) Dalbeth N, et al : Population-specific effects of SLC17A1 genotype on serum urate concentrations and renal excretion of uric acid during a fructose load. Ann Rheum Dis 73 : 313-314, 2014.
PubMed
P.113 掲載の参考文献
1) Duncan H, Dixon AS : Gout, famihal hyperuricaemia, and renal disease. Q J Med 29 : 127-135, 1960.
 
2) Hart TC, et al : Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 39 : 882-892, 2002.
PubMed
3) Rampoldi L, et al : Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12 : 3369-3384, 2003.
PubMed
4) Ekici AB, et al : Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. Kidney Int 86 : 589-599, 2014.
PubMed
5) Eckardt KU, et al : Autosomal dominant tubulointerstitial kidney disease : diagnosis, classification, and management-A KDIGO consensus report. Kidney Int 88 : 676-683, 2015,
PubMed
6) Venkat-Raman G, et al : From juvenile hyperuricaemia to dysfunctional uromodulin : an ongoing metamorphosis. Pediatr Nephrol, 2016. [Epub ahead of print]
 
7) Dahan K et al : A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 14 : 2883-2893, 2003.
PubMed
8) Bernascone I, et al : A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure. Hum Mol Genet 19 : 2998-3010, 2010.
 
9) Takiue Y, et al : Enhancement of androgen action in the kidneys of transgenic mice harboring the mutant human UMOD gene. J Pharmacol Sci 115 : 383-389, 2011.
 
10) Zaucke F, et al : Uromodulin is expressed in renal primary cilia and UMOD mutations result in decreased ciliary uromodulin expression. Hum Mol Genet 19 : 1985-1997, 2010.
 
11) Moskowitz JL, et al : Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol 8 : 1349-1357, 2013.
PubMed
12) Zivna M, et al : Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet 85 : 204-213, 2009.
PubMed
13) Heidet L, et al : Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol 5 : 1079-1090, 2010.
 
14) Gresh L, et al : A transcriptional network in polycystic kidney disease. EMBO J 23 : 1657-1668, 2004.
PubMed
15) Piret SE, et al : Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22.1-p21. Hum Genet 129 : 51-58, 2011.
PubMed
P.119 掲載の参考文献
1) Seegmiller JE, et al : Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science 155 : 1682-1684, 1967.
PubMed
2) Kelley WN, et al : A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci USA 57 : 1735-1739, 1967.
PubMed
3) Fu R, et al : Genotype-phenotype correlations in neurogenetics : Lesch-Nyhan disease as a model disorder. Brain 137 : 1282-1303, 2014.
 
4) Yamada Y, et al : Hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiencies : HPRT1 mutations in new Japanese families and PRPP concentration. Nucleosides Nucleotides Nucleic Acids 33 : 218-222, 2014.
PubMed
5) Jinnah HA, et al : Attenuated variants of Lesch-Nyhan disease. Brain l33 : 671-689, 2010.
 
6) Jinnah HA, et al : Delineation of the motor disorder of Lesch-Nyhan disease. Brain 129 : 1201-1217, 2006.
PubMed
7) Yamada Y, et al : Molecular analysis of HPRT deficiencies : an update of the spectum of Asian mutations with novel mutations. Mol Genet Metab 90 : 70-76, 2007.
 
8) Torres Rl, Puig JG : Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency : Lesch-Nyhan syndrome. Orphanet J Rare Dis 2 : 48, 2007.
 
9) Tatibana M, et al : Mammalian phosphoribosyl-pyrophosphate synthetase. Adv Enzyme Regul 35 : 229-249, 1995.
PubMed
10) Becker MA, et al : The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest 96 : 2133-2141, 1995.
PubMed
11) Roessler BJ, et al : Human X-linked phosphoribosylpyrophosphate synthetase superactivity is associated with distinct point mutations in the PRPS1 gene. J Biol Chem 268 : 26476-26481, 1993.
 
12) de Brouwer APM, et al : PRPS1 mutations : four distinct syndromes and potential treatment. Am J Hum Genet 86 : 506-518, 2010.
PubMed
13) Kamatani N, et al : Purine pyrimidine metabolism. In : Principles and Practice of Medical Genetics (ed by Rimoin DL, et al), 5th ed, p 2222-2246, Elsevier, Philadelphia, 2007.
 
14) Becker MA : Hyperuricemia and gout. In : The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR et al), Vol II, 8th ed, p 2513-2535, McGraw-Hill, New York, 2001.
 
P.123 掲載の参考文献
1) Mandal AK, Mount DB : The molecular physiology of uric acid homeostasis. Annu Rev Physiol 77 : 323-345, 2015.
PubMed
2) Torres RJ, et al : Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol 41 (9) : 1863-1870, 2014.
PubMed
3) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
4) Berni A, et al : Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers. Am J Hypertens 23 : 675-680, 2010.
PubMed
5) Bacchetta J, et al : Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol 27 (7) : 1131-1138, 2012.
PubMed
6) Zhou J, et al : Plasma uric acid level indicates tubular interstitial lesions at early stage of IgA nephropathy. BMC Nephrol 15 : 11, 2014.
PubMed
7) Weaver VM, et al : Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. Environ Health Perspect l 13 (11) : 1509-1515, 2005.
 
8) 中村賢治ほか : 現在も発生する塗装工の鉛中毒. 産業衛生学雑誌 57 (5) : 241-243, 2015.
Medical*Online
9) Kaehny WD, et al : Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 89 (1) : 49-52, 1990.
PubMed
10) Han M, et al : Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 15 : 63, 2014.
PubMed
11) Eckardt KU, et al : Autosomal dominant tubulointerstitial kidney disease : diagnosis, classification, and management-A KDIGO consensus report. Kidney Int 88 (4) : 676-683, 2015.
PubMed
12) Scolari F, et al : Uromodulin : from monogenic to multifactorial diseases. Nephrol Dial Transplant 30 (8) : 1250-1256, 2015.
PubMed
13) Zivna M, et al : Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet 85 : 204-213, 2009.
PubMed
14) Kashima A, et al : Children with Down's syndrome display high rates of hyperuricemia. Acta Paediatr 103 (8) : e359-364, 2014.
PubMed
15) Campos C, et al : Urinary uric acid and antioxidant capacity in children and adults with Down syndrome. Clin Biochem 43 (3) : 228-233, 2010.
PubMed
P.129 掲載の参考文献
1) 第2章 4 二次性高尿酸血症・痛風. 高尿酸血症・痛風の治療ガイドライン, 第2版, p 69-72, メディカルレビュー社, 2010.
 
2) Coiffier B, et al : Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. J Clin Oncol 26 : 2767-2778, 2008.
PubMed
3) Cairo MS, et al ; TLS Expert Panel : Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol 149 : 578-586, 2010.
 
4) 腫瘍崩壊症候群 (TLS) 診療ガイダンス (日本臨床腫瘍学会編), 2013.
 
5) Yamauchi T, et al : A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 33 : 3947-3951, 2013.
PubMed
6) Zurcher RM, et al : Hyperuricaemia in cyclosporin-treated patients : GFR-related effect. Nephrol Dial Transplant 11 : 153-158, 1996.
PubMed
7) European Multicenter Trial Group : Cyclosporine in cadaveric renal transplantation : one-year follow-up of a multicenter trial. Lancet 2 : 986-989, 1983.
PubMed
8) Laine J, Holmberg C : Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron 74 : 318-323, 1996.
PubMed
9) Tostivint I, et al : Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 22 : 880-885, 2007.
PubMed
10) Kanbay M, et al : Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 37 : 3119-3120, 2005.
PubMed
P.134 掲載の参考文献
1) See LC, et al : Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia. PLoS One 9 : e114579, 2014.
PubMed
2) Giordano N, et al : Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 19 : 661-666, 2001.
 
3) Sato A, et al : Hyperuricemia in patients with hyperthyroidism due to Graves' disease. Metabolism 44 : 207-211, 1995.
PubMed
4) Pepersack T, et al : Hyperuricemia and renal handling of urate in primary hyperparathyroidism. Nephron 53 : 349-352, 1989.
PubMed
5) Neer RM, et al : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 : 1434-1441, 2001.
PubMed
6) Hui JY, et al : The independent association between parathyroid hormone levels and hyperuricemia : a national population study. Arthritis Res Ther 14 : R56, 2012.
PubMed
7) Cappuccio FP, et al : Uric acid metabolism and tubular sodium handling : results from a population-based study. JAMA 270 : 354-359, 1993.
PubMed
8) Collazo R et al : Acute regulation of Na+/H+ exchanger NHE3 by parathyroid hormone Via NHE3 phosphorylation and dynamin-dependent endocytosis. J Biol Chem 275 : 31601-31608, 2000.
PubMed
9) Dwosh IL, et al : Hypouricemia in disease : a study of different mechanisms. J Lab Clin Med 90 : 153-161, 1977.
PubMed
10) Faggiano A, et al : Nephrolithiasis in Cushing's disease : Prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88 : 2076-2080, 2003.
 
11) Rubin RT, et al : Serum uric acid, cholesterol, and cortisol intercorrelations in normoactive subjects. Am Heart J 81 : 843-845, 1971.
PubMed
12) Adams BM : Effect of cortisol on growth and uric acid excretion in the chick. J Endocrinol 40 : 145-151, 1968.
 
13) Sumino H, et al : Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricemia. Lancet 354 : 650, 1999.
PubMed
14) Hosoyamada M, et al : The effect of testosterone upon the urate reabsorptive transport system in mouse kidney. Nucleosides Nucleotides Nucleic Acids 29 : 574-579, 2010.
PubMed
15) 細山田真 : 血清尿酸値の性差のメカニズム. 高尿酸血症と痛風 18 : 131-134, 2010.
Medical*Online
P.140 掲載の参考文献
1) Fox IH, et al : Hyperuricemia : a marker for cell energy crisis. N Engl J Med 317 : 111-112, 1987.
PubMed
2) 嶺尾郁夫ほか : グリコーゲン病 (糖原病) による高尿酸血症. 高尿酸血症と痛風 11 : 38-43, 2003.
Medical*Online
3) 河野典夫ほか : グリコーゲン病 (糖原病). 日本臨牀 51 (増刊 : 本邦臨床統計集 (下)) : 285-296, 1993.
 
4) 土井喜宣ほか : グリコーゲン病I型 (von Gierke病) における高尿酸血症の発現機序 : 肝糖代謝異常とプリン異化亢進との関連性について. Purine and Pyrimidine Metabolism 17 : 1-9, 1993.
 
5) Cohen JL, et al : Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production. J Clin Invest 75 : 251-257, 1985.
PubMed
6) Greene HL, et al : ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I. J Clin Invest 62 : 321-328, 1978.
PubMed
7) Mineo I, et al : Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII. J Clin Invest 76 : 556-560, 1985.
 
8) Mineo I, et al : A comparative study on glucagon effect between McArdle disease and Tarui disease. Muscle Nerve 7 : 552-559, 1984.
PubMed
9) Hers HG, et al : Glycogen storage diseases. In : Metabolic Basis of Inherited Disease, 6th ed (ed by Scriber CR et al), p 425-452, McGraw-Hill, New York, 1989.
 
10) Musumeci O, et al : Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord 22 : 325-330, 2012.
PubMed
11) Drouet A, et al : Exercise-induced muscle pain due to phosphofructokinase deficiency : Diagnostic contribution of metabolic explorations (exercise tests, 31P-nuclear magnetic resonance spectroscopy). Rev Neurol (Paris) 169 : 613-624, 2013.
PubMed
12) Mineo I, et al : Glucose infusion abolishes the excessive ATP degradation in working muscles of a patient with McArdle'sdisease. Muscle Nerve 13 : 618-620, 1990.
 
13) Kitaoka Y, et al : Oxidative stress and Nrf2 signaling in McArdle disease. Mol Genet Metab 110 : 297-302, 2013.
PubMed
14) Mineo I, et al : Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 317 : 75-80, 1987.
 
15) Mineo I, Tarui S : Myogenic hyperuricemia : what can we learn from metabolic myopathies? Muscle Nerve 3 (Suppl) : S75-81, 1995.
PubMed
P.144 掲載の参考文献
1) Fuller RW, et al : Serum uric acid in mongolism. Science 137 (3533) : 868-869, 1962.
PubMed
2) 二次性高尿酸血症・痛風. 高尿酸血症・痛風の治療ガイドライン (第2版), p69-72, メディカルレビュー社, 2010.
 
3) World Health Organization, Genes and chromosomal diseases, Down syndrome. [http://www.who.int/genomics/public/geneticdiseases/en/index1.html]
 
4) Pant SS, et al : Hyperuricemia in Down's syndrome. J Clin Endocrinol Metab 28 : 472-478, 1968,
PubMed
5) 岡部英明ほか : Down症候群に合併する痛風, 高尿酸血症の検討. 痛風と核酸代謝 28 : 19-26, 2004.
 
6) 植田紀美子ほか : ダウン症候群を持つ成人の健康管理に関する調査-肥満とメタボリックシンドロームに着目して-. 日本遺伝カウンセリング学会誌 32 : 101-107, 2011.
Medical*Online
7) Zitnanova I, et al : Uric acid and allantoin levels in Down syndrome : antioxidant and oxidative stress mechanisms? Clin Chim Acta 341 : 139-146, 2004.
PubMed
8) Garcez ME, et al : Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 80 : 1607-1611, 2005.
PubMed
9) Yoshida Y, Yasuhara A : Study on hyperuricemia in patients with Down syndrome. Clin Pediat Endocri 11 : 129, 2002.
 
10) 久保田優 : 小児科領域の高尿酸血症, 痛風と核酸代謝 33 : 37-43, 2009.
 
11) 村松友佳子ほか : ダウン症候群小児における血清尿酸値の検討. 痛風と核酸代謝 34 : 41, 2010.
 
12) Kashima A, et al : Children with Down's syndrome display high rates of hyperuricemia. Acta Paediatr 103 : e359-364, 2014.
PubMed
13) 谷口敦夫 : ダウン症-最近の話題-5. ダウン症と高尿酸血症. 小児科臨床 64 : 2123-2129, 2011.
 
14) Cobum SP, et al : Metabolism of N15 labeled uric acid in Down's syndrome. Metabolism 17 : 560-562, 1968.
 
15) Nishida Y, et al : Renal impairment in urate excretion in patients with Down's syndrome. J Rheumatol 6 : 103-107, 1979.
PubMed
16) Malaga S, et al : Renal involvement in Down syndrome. Pediatr Nephrol 20 : 614-617, 2005.
PubMed
17) Puukka R et al : Erythrocytes adenosine deaminase, purine nucleoside phosphorylase and phosphoribosyltransferase activity in patients with Down'ssyndrome, Clin Chim Acta 126 : 275-281, 1982.
 
18) Lin JD, et al : Serum uric acid, hyperuricemia and body mass index in children and adolescents with intellectual disabilities. Res Dev Disabil 30 : 1481-1489, 2009.
PubMed
19) Helma BM, et al : Prevalence of overweight in Dutch children with Down syndrome. Pediatrics 130 : e1520-e1526, 2012.
 
20) 中佳久, 小谷裕実 : 近畿地方における知的障害児の肥満実態調査および肥満指導に関する一考察-第2報-. 小児保健研究 26 : 26-33, 2003.
Medical*Online
21) Ciompi ML, et al : Uric acid metabolism in two patients with coexistent Down's syndrome and gout. Clin Rheumatol 3 : 229-233, 1984.
PubMed
22) Kamatani N, et al : Down syndrome with coexistent gout : report of six patients and possible reasons for the scarcity of descriptions of this association. Ann Rheum Dis 55 : 649-650, 1996.
PubMed
23) 加藤玲奈ほか : 小児期および思春期に発症した痛風に関する全国調査. 痛風と核酸代謝 38 : 43-48, 2014.
 
24) 中島亜矢子, 山中寿 : 特集 遺伝子異常と高尿酸血症および低尿酸血症. Down症候群. 高尿酸血症と痛風 10 : 60-64, 2002.
 
25) Campos C, et al : Urinary uric acid and antioxidant capacity in children and adults with Down syndrome. Clin Biochem 43 : 228-233, 2010.
PubMed
26) Garlet TR, et al : Systemic oxidative stress in children and teenagers with Down syndrome. Life Sci 93 : 558-563, 2013.
PubMed
P.150 掲載の参考文献
1) 妊娠高血圧症候群の診療指針 2015 (日本妊娠高血圧学会編), メジカルビュー社, 2015.
 
2) Suzuki Y, et al : Mechanisms underlying the reduced endothelium-dependent relaxation in human omental resistance artery in pre-eclampsia. J Physiol 527 : 163-174, 2000.
PubMed
3) Suzuki Y, et al : Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. J Physiol 545 : 269-277, 2002.
PubMed
4) Yamamoto T, et al : Reduced flow-mediated vasodilatation is not due to a decrease in production of nitric oxide in preeclampsia. Am J Obstet Gynecol 192 : 558-563, 2005.
 
5) Cunningham FG, et al : Hypertensive disorders. In : Williams Obstetrics, 24th ed, p728-729, McGraw-Hill, New York, 2014.
 
6) Saito S : Cytokine cross-talk between mother and the embryo/placenta. J Reprod Immunol 52 : 15-33, 2001.
PubMed
7) Nagamatsu T, et al : Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen : an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145 : 4838-4845, 2004.
PubMed
8) Khaliq A, et al : Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression : molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest 79 : 151-170, 1999.
PubMed
9) Gant NE et al : A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 52 : 2682-2689, 1973.
 
10) Wallukat G, et al : Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103 : 945-952, 1999.
PubMed
11) Yamamoto T, et al : Characteristic changes in calcium metabolism in preeclamptic women in Japan. Hypertens Res Pregnancy 1 : 108-112, 2013.
 
12) Watanabe K et al : Increased oxidant generation in the metabolism of hypoxanthine to uric acid and endothelial dysfunction in early-onset and late-onset preeclamptic women. J Matem Fetal Neonatal Med 25 : 2662-2666, 2012.
 
13) Itoh T, et al : Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol 548 : 893-906, 2003.
PubMed
14) Yamamoto T, et al : Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery. Br J Pharmacol 146 : 534-542, 2005.
PubMed
P.154 掲載の参考文献
1) 多田弥生 : BenchとBedsideを行き来するうちにわかってきた乾癬の病態. 皮膚科の臨床 56 : 1141-1151, 2014.
 
2) Gelfand JM, et al : Risk of myocardial infarction in patients with psoriasis. JAMA 296 : 1735-1741, 2006.
PubMed
3) Prodanovich S, et al : Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145 : 700-703, 2009.
PubMed
4) Wan J, et al : Risk of moderate to advanced kidney disease in patients with psoriasis : population based cohort study. BMJ 347 : f5961, 2013.
PubMed
5) Boehncke WH, et al : The 'psoriatic march' : a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20 : 303-307, 2011.
 
6) Goldman M : Uric acid in the etiology of psoriasis. Am J Dermatopathol 3 : 397-404, 1981.
PubMed
7) Peserico A, et al : Relationship between body weight and blood pressure and some metabolic parameters in psoriatic patients. Br J Dermatol 118 : 191-194, 1988.
PubMed
8) Bruce IN, et al : Hyperuricemia in psoriatic arthritis : prevalence and associated features. J Clin Rheumatol 6 : 6-9, 2000.
PubMed
9) Merola JF, et al : Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 74 : 1495-1500, 2015.
PubMed
10) Feuerman EJ, Nir MA : Allopurinol in psoriasis-a double-blind study. Br J Dermatol 89 : 83-86, 1973.
PubMed
11) Chen JH, et al : Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality : a chinese cohort study. Arthritis Rheum 61 : 225-232, 2009.
PubMed
12) Gonzalez-Gay MA, et al : Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 39 : 157-162, 2009.
PubMed
13) Oliviero F, et al : Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine 80 : 287-290, 2014.
 
14) Martinon F, et al : Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 : 237-241, 2006.
PubMed
15) Uratsuji H, et al : P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. J Immunol 188 : 436-444, 2012.
PubMed
P.160 掲載の参考文献
1) Hagos Y, et al : Torasemide transport by organic anion transporters contributes to hyperuricemia. J Am Soc Nephrol 18 : 3101-3109, 2007.
PubMed
2) El-Sheikh AA, et al : Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 155 : 1066-1075, 2008.
PubMed
3) Hasegawa M, et al : Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 18 : 37-45, 2007.
PubMed
4) Hasannejad H, et al : Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308 : 1021-1029, 2004.
PubMed
5) Hagos Y, et al : Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18 : 430-439, 2007.
PubMed
6) Jutabha P, et al : Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 285 : 35123-35132, 2010.
PubMed
7) Yamamoto T, et al : Effect of lactate infusion on rena1 transport of purine bases and oxypurinol. Nephron 65 : 73-76, 1993.
 
8) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
9) Bahn A, et al : Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 283 : 16332-16341, 2008.
PubMed
10) Yamamoto T, et al : Effect of ethanol and fructose on plasma uridine and purine bases. Metabolism 46 : 544-547, 1997.
PubMed
11) Nakagawa T, et al : Hypothesis : fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 1 : 80-86, 2005.
PubMed
12) Korttila K, Mattila MA : Increased serum concentrations of lactic, pyruvic and uric acid and bilirubin after postoperative xylitol infusion. Acta Anaesth Scand 23 : 273-277, 1979.
PubMed
13) Yamamoto T, et al : Theophylline-induced increase in plasma uric acid-purine catabolism increased by theophylline. Int J Clin Pharmacol Ther Toxicol 29 : 257-261, 1991.
PubMed
14) Ohtsu N, et al : Human renal urate transpoter URAT1 mediates the transport of salicylate. Nippon Jinzo Gakkai Shi 52 : 499-504, 2010.
PubMed
15) Khamdang S, et al : Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303 : 534-539, 2002.
PubMed
P.165 掲載の参考文献
1) Choi HK, et al : Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350 : 1093-1103, 2004.
 
2) Choi HK, Curhan G : Beer, liquor, and wine consumption and senlm uric acid level : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 51 : 1023-1029, 2004.
 
3) 高尿酸血症・痛風の生活指導. 高尿酸血症・痛風の治療ガイドライン, 第2版, p110-112, メディカルレビュー社, 2010.
 
4) Zhang Y, et al : Purine-rich foods intake and recurrent gout attackes. Ann Rheum Dis 71 : 1448-1453, 2012.
 
5) Kaneko K, et al : Determination of purine contents of alcoholic beverages using high performance liquid chromatography. Biomed Chromatogr 23 : 858-864, 2009.
PubMed
6) Kaneko K, et al : Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperiricemia. Biol Pharm Bull 37 : 709-721, 2014.
PubMed
7) 金子希代子ほか : 食品中プリン体含量および塩基別含有率の比較. 痛風と核酸代謝 39 : 7-21, 2015.
 
8) Gibson T, et al : A controlled study of diet in patients with gout Ann Rheum Dis 42 : 123-127, 1983.
 
9) Choi HK, et al : Alcohol intake and risk of incident gout in men ; A prospective study. Lancet 363 : 1277-1284, 2004.
 
10) Choi HK, Curhan G : Soft drinks, fructose consumption, and the risk of gout in men : prospective cohort study. Brit Med J 336 : 309-312, 2008.
PubMed
11) Williams PT : Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 87 : 1480-1487, 2008.
PubMed
12) Ohno M, et al : Effects of exercise and grape juice ingestion in combination on plasma concentrations of purine bases and uridine. Clin Chim Acta 388 : 167-172, 2008.
PubMed
13) Dalbeth N, et al : Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. Arthritis Res Ther 17 : 263-269, 2015.
PubMed
14) Lin WT, et al : Fructose-rich beverage intake and central adiposity, uric acid, and pediatric insulin resistance. J Pediatr 171 : 90-96, 2016.
PubMed
P.170 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会高尿酸血症・痛風の治療ガイドライン作成委員会編), 日本痛風・核酸代謝学会, 2010.
 
2) 加藤尚志 : 臨床医化学分析における標準化の現状と課題. 産総研計量標準報告 5 (1) : 81-95, 2006.
 
3) 影山信雄 : 現在行なわれている尿酸測定法の特徴と問題点. 尿酸 7 (2) : 225-234, 1983.
 
4) 血清尿酸値正常領域決定のための小委員会 : 尿, 血清尿酸正常値決定のための尿酸測定法 (1987). 尿酸 11 (2) : 156-166, 1987.
 
5) 金井正光 (編著) : 臨床検査法提要 第32版, 金原出版, 2005.
 
6) 石田尚志, 小澤定延 : 多層フィルム式スライドによる血中尿酸測定法の検討. 生物試料分析 8 (3) : 57-60, 1985.
Medical*Online
7) 福井巌ほか : Uricase酸素電極法による血清尿酸の測定に関する検討. 日本老年医学会雑誌 11 (1) : 20-28, 1974.
 
8) 土田寿男, 依田賢太郎 : 過酸化水素透過膜へのウリカーゼの固定化と酵素電極への応用. 日本化学会誌 1982 (8) : 1347-1351, 1982.
 
9) 日本臨床化学会試薬専門委員会 : HPLCを用いる血清尿酸測定法の勧告法. 臨床化学 22 : 300-307, 1993.
 
10) 酒井伸枝ほか : キャピラリー電気泳動による健常人および糖尿病発症初期患者の尿成分分析. 生物物理化学 42 : 123-129, 1998.
Medical*Online
P.173 掲載の参考文献
1) 中村徹 : 高尿酸血症における尿酸代謝動態. 日本臨牀 31 (5) : 1161-1172, 1973.
Medical*Online
2) 第1章 1 高尿酸血症の定義高尿酸血症・痛風の治療ガイドライン, 第2版, p30-31, メディカルレビュー社, 2010.
 
3) 第2章 2 高尿酸血症の病型分類. 高尿酸血症・痛風の治療ガイドライン, 第2版, p 63-65, メディカルレビュー社, 2010.
 
4) 中村徹ほか : 痛風高尿酸血症の尿酸クリアランス法による検討. 尿酸 1 : 45-61, 1977.
 
5) 中村徹ほか : 痛風の高尿酸血症の尿酸クリアランス法による検討. 尿酸 2 : 125-130, 1978.
 
6) 大田祐子ほか : 高血圧患者における高尿酸血症の病型分類 : 簡便法の有用性について. 痛風と核酸代謝 35 : 169-174, 2011.
 
7) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
P.181 掲載の参考文献
1) 新名正由 : 関節穿刺と関節液検査. 最新内科学大系 25 (井村裕夫ほか編), p 143-148, 中山書店, 1993.
 
2) Chen LX, Schumacher HR : Gout : can we create an evidence-based systematic approach to diagnosis and management? Best Pract Res Clin Rheumatol 20 : 673-684, 2006.
PubMed
3) 西田圭一郎 : 痛風. 整形外科専門医テキスト (長野昭ほか編), p269-273, 南江堂, 2010.
 
4) Gerster JC, et al : Imaging of tophaceous gout : computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61 : 52-54, 2002.
PubMed
5) 八野田愛ほか : 四肢に発生した多発性痛風結節の1例. 中部日本整形外科災害外科学会雑誌 57 : 379-380, 2014.
 
6) Choi HK, et al : Dual energy CT in gout ; a prospective validation study. Ann Rheum Dis 71 : 1466-1471, 2012.
 
7) Baer AN, et al : Dual-energy computed tomography has limited sensitivity for non-tophaceous gout : a comparison study with tophaceous gout. BMC Musculoskelet Disord 17 : 91, 2016.
 
P.186 掲載の参考文献
1) Puig JG, et al : Asymptomatic hyperuricemia : impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 27 : 592-595, 2008.
PubMed
2) Pineda C, et al : Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia : an ultrasound controlled study. Arthritis Res Ther 13 : R4, 2011.
PubMed
3) de Miguel E, et al : Diagnosis of gout in patients with asymptomatic hyperuricemia : a pilot ultrasound study. Ann Rheum Dis 71 : 157-158, 2012.
PubMed
4) Schueller-Weidekamm C, et al : Impact of sonography in gouty arthritis : comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 62 : 437-443, 2007.
PubMed
5) Carter JD, et al : An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology 48 : 1442-1446, 2009.
PubMed
6) Wright SA, et al : High-resolution ultrasonography of the first metatarsal phalangeal joint in gout : a controlled study. Ann Rheum Dis 66 : 859-864, 2007.
 
7) Grassi W, et al : "Crystal clear" -sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum 36 : 197-202, 2006.
PubMed
8) Gutierrez M, et al : International consensus for ultrasound lesions in gout : results of Delphi process and web-reliability exercise. Rheumatology (Oxford) 54 : 1797-1805, 2015.
PubMed
9) Gutierrez M, et al : Calcium pyrophosphate crystals detected by ultrasound in patients without radiographic evidence of cartilage calcifications. J Rheumatol 37 : 2602-2603, 2010.
PubMed
10) Ottaviani S, et al : Sensitivity and reproducibility of ultrasonography in calcium pyrophosphate crystal deposition in knee cartilage : a cross-sectional study. J Rheumatol 42 : 1511-1513, 2015.
PubMed
11) Ogdie A, et al : Imaging modalities for the classification of gout : systematic literature review and meta-analysis. Ann Rheum Dis 74 : 1868-1874, 2015.
PubMed
12) Neogi T, et al : 2015 Gout classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74 : 1789-1798, 2015.
PubMed
13) Thiele RG, Schlesinger N : Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 30 : 495-503, 2010.
PubMed
14) Perez-Ruiz F, et al : Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 34 : 1888-1893, 2007.
 
15) 瀬戸洋平ほか : 痛風患者における母趾中足基節関節超音波検査による結晶沈着所見と関節症性変化の関連について. 痛風と核酸代謝 39 : 86, 2015.
 
P.192 掲載の参考文献
1) Durcan L, et al : Imaging as a potential outcome measure in gout studies : A systemic literature review. Semin Arthritis Rheum 45 : 570-579, 2016.
 
2) Neogi T, et al : 2015 Gout classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74 : 1789-1798, 2015.
PubMed
3) McCollough CH, et al : Dual-and multi-energy CT : principles, technical approaches, and clinical applications. Radiology 276 : 637-653, 2015.
PubMed
4) 町田治彦ほか : 痛風のためのdual-energy CTの現状. 高尿酸血症と痛風 23 : 62-67, 2015.
Medical*Online
5) 町田治彦ほか : 痛風のためのdual-energy CTの基本原理と臨床応用. 高尿酸血症と痛風 21 : 41-46, 2013.
 
6) Gerster JC, et al : Imaging of tophaceous gout : computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61 : 52-54, 2002.
PubMed
7) Choi HK, et al : Dual energy CT in gout : a prospective validation study. Ann Rheum Dis 71 : 1466-1471, 2012.
 
8) Mallinson PI, et al : Artifacts in dual-energy CT gout protocol : a review of 50 suspected cases with an artifact identification guide. AJR Am J Roentgenol 203 : W103-W109, 2014.
PubMed
9) Ogdie A, et al : Imaging modalities for the classification of gout : systematic literature review and meta-analysis. Ann Rheum Dis 74 : 1868-1874, 2015.
PubMed
10) Huppertz A, et al : Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 34 : 763-771, 2014.
PubMed
11) Desai MA, et al : Clinical utility of dua;-energy CT for evaluation of tophaceous gout. Radiographics 31 : 1365-1375, 2011.
 
12) Delbeth N, et al : Urate crystal decomposition in asymptomatic hyperuricemia and symptomatic gout : a dual energy CT study. Ann Rheum Dis 74 : 908-911, 2015.
 
13) Finkenstaedt T, et al : Gouty arthritis : the diagnostic and therapeutic impact of dual-energy CT. Eur Radiol, 2016. [Epub ahead of print].
 
14) Metzger SC, et al : Dual-energy CT in patients with suspected gouty arthritis : effects on treatment regimen and clinical outcome. Acad Radiol 23 : 267-272, 2016.
PubMed
P.198 掲載の参考文献
1) 日本痛風・核酸代謝学会ガイドライン改訂委員会編 : 高尿酸血症・痛風の治療ガイドライン (第2版), メディカルレビュー社, 2010.
 
2) 御巫清允 : 痛風の臨床, 旧来の認識を改めよ. 医事新報 2577 : 10, 1973.
 
3) 作山理子ほか : 痛風発作を誘発しないための血清尿酸値の維持水準に関する研究. プリン・ピリミジン代謝 17 : 81-89, 1993.
 
4) Perez-Ruiz F, et al : Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47 : 356-360, 2002.
 
5) Kumar S, Gow P : A survey of indications, results and complications of surgery for tophaceous gout. N Z Med J 115 : U109, 2002.
 
6) Shibagaki Y, et al : Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37 : 919-925, 2014.
PubMed
7) Sircar D, et al : Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia : A6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis 66 : 945-950, 2015.
PubMed
8) Hosoya T, et al : The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3 : study protocol for a multicenter randomized controlled study. Trials 15 : 26, 2014.
PubMed
9) Hosoya T, et al : Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18 : 876-884, 2014.
PubMed
10) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
P.203 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン (第2版) 2012年追補版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2012.
 
2) 中島弘ほか : 痛風・高尿酸血症の診療指針に関するコンセンサス・カンファランス (1996) と痛風専門医の診療実態調査結果の報告. プリン・ピリミジン代謝 20 : 154-158, 1996.
 
3) Shoji A, et al : A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51 : 321-325, 2004.
PubMed
4) Campion EW, et al : Asymptomatic hyperuricemia ; Risks and consequences in the Normative Aging Study. Am J Med 82 : 421-426, 1987.
PubMed
5) Schumacher HR Jr, et al : Febuxostat in the treatment of gout ; 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48 : 188-194, 2009.
PubMed
6) Zhang W, et al ; EULAR Standing Committee for International Clinical Studies Including Therapeutics : EULAR evidence based recommendations for gout. Part II ; Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 : 1312-1324, 2006.
PubMed
7) Perez-Ruiz F, et al : Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy : a prospective study. Arthritis Rheum 55 : 786-790, 2006.
PubMed
8) 細谷龍男ほか : 無症候性高尿酸血症の予後に関する研究. リウマチ 25 : 369-371, 1986.
 
9) Zhu P, et al : Serum uric acid is associated with incident chronic kidney disease in middle-aged populations : a meta-analysis of 15 cohort studies. PLoS One 9 : e100801, 2014.
PubMed
10) Lin JL, et al : Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int 60 : 266-271, 2001.
PubMed
11) Kuwabara M, et al : Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 37 : 785-789, 2014.
 
12) Soletsky B, et al : Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60 : 1148-1156, 2012.
PubMed
13) Noman A, et al : Effect of high-dose allopurinol on exercise in patients with chronic stable angina : a randomized, placebo controlled crossover tria1. Lancet 375 : 2161-2167, 2010.
 
14) Tamariz L, et al : Association between serum uric acid and atrial fibrillation : a systematic review and meta-analysis. Heart Rhythm 11 : 1102-1108, 2014.
PubMed
15) Li M, et al : Hyperuricemia and risk of stroke : a systematic review and meta-analysis of prospective studies. Atherosclerosis 232 : 265-270, 2014.
PubMed
16) Tsutani H, et al : Latent overproductive hyperuricemia increases in patients during the intermittent phase of gouty arthritis under long-term antihyperuricemic treatment. Mod Rheumatol 10 : 207-210, 2000.
PubMed
P.207 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p79-82, メディカルレビュー社, 2010.
 
2) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p 110-112, メディカルレビュー社, 2010.
 
3) Nakamura K et al : Alcohol intake and the risk of hyperuricaemia : a 6-year prospective study in Japanese men. Nutr Metab Cardiovasc Dis 22 : 989-996, 2012.
PubMed
4) Ren Z, et al : The consumption of fish cooked by different methods was related to the risk of hyperuricemia in Japanese adults : A 3-year follow-up study. Nutr Metab Cardiovasc Dis 26 : 778-785, 2016.
 
5) Kelishadi R, et al : Association of fructose consumption and components of metabolic syndrome in human studies : a systematic review and meta-analysis. Nutrition 30 : 503-510, 2014.
PubMed
6) Perez-Pozo SE, et al : Excessive fructose intake induces the features of metabolic syndrome in healthy adult men : role of uric acid in the hypertensive response. Int J Obes (Lond) 34 : 454-461, 2010.
PubMed
7) Choi JW, et al : Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 59 : 109-116, 2008.
PubMed
8) Johnson RI, et al : Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62 : 3307-3315, 2013.
 
P.215 掲載の参考文献
1) 山本徹也 : 高尿酸血症・痛風の原因 尿酸排泄低下型. 高尿酸血症・痛風 (寺井千尋編), p37-43, 最新医学社, 2015.
 
2) 山崎知行ほか : いわゆる筋原性高尿酸血症の概念. 日本臨牀 54 (12) : 161-165, 1996.
 
3) 石田浩之 : スポーツによる内科的障害. スポーツ医学研修ハンドブック応用科目 (日本体育協会指導者育成専門委員会スポーツドクター部門監修), p62-75, 文光堂, 2011.
 
4) 小笠原正志ほか : 運動強度の差がammoniaおよびoxypurines動態に及ぼす影響. 体力科学 37 : 85-92, 1998.
 
5) Arakawa K, et al : Changes in blood biochemical markers before, during, and after a 2-day ultramarathon. Open Access J Spots Med 7 : 43-50, 2016.
 
6) Williams PT : Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. Arch Intern Med 157 : 191-198, 1997.
PubMed
7) Nishida Y, et al : Influence of physical actiVity intensity and aerobic fitness on the anthropometric index and serum uric acid concentration in people with obesity. Intern Med 50 : 2121-2128, 2011.
PubMed
8) Beavers KM, et al : The effect of a long-term physical activity intervention on serum uric acid on older adults at risk for physical disability. J Aging Phys Act 22 : 25-33, 2014.
PubMed
P.220 掲載の参考文献
1) 痛風関節炎・痛風結節の治療. 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p74-78, メディカルレビュー社, 2010.
 
2) Khanna D, et al : 2012 American College of Rheumatology guidelines for management of gout. Part 2 : therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arth Care Res 10 : 1447-1461, 2012.
 
3) Martinon F, et al : Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 : 237-241, 2006.
PubMed
4) Misawa T, et al : Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 14 : 454-460, 2013.
PubMed
5) 御巫清允ほか : ナプロキセンの痛風発作に対する臨床効果 ; 二重盲検法によるフェニルブタゾンとの比較及び尿酸代謝動態への影響の検討. 臨床と研究 58 : 999-1010, 1981.
Medical*Online
6) Schumacher HR, et al : Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis : a randomized controlled trial. J Rheumatol 39 : 1859-1866, 2012.
PubMed
7) Chen K, et al : Anakinra's efficacy is variable in refractory gout : report of ten cases. Semin Arthritis Rheum 40 : 210-214, 2010.
PubMed
8) Zhang W, et al : EULAR evidence based recommendations for gout. Part II : Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT), Ann Rheum Dis 65 : 1312-1324, 2006.
PubMed
9) Man CY, et al : Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetarnol combination therapy in the treatment of acute goudike arthritis : a double-blind, randomized, controlled trial. Ann Emerg Med 49 : 670-677, 2007.
PubMed
10) Janssens HJ, et al : Use of oral prednisolone or naproxen for the treatment of gout arthritis : a double-blind, randomised equivalence trial. Lancet 2371 : 1854-1860, 2008.
 
P.224 掲載の参考文献
1) 痛風関節炎・痛風結節の治療. 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p74-78, メディカルレビュー社, 2010.
 
2) 瀬戸洋平 : 痛風 (日本リウマチ財団教育研修委員会・日本リウマチ学会生涯教育委員会編), p330-335, 診断と治療社, 2016.
 
3) Schumacher HR, et al : Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis : a randomized controlled trial. J Rheumatol 39 : 1859-1866, 2012.
PubMed
4) Janssens HJ, et al : Use of oral prednisolone or naproxen for the treatment of gout arthritis : a double-blind, randomised equivalence trial. Lancet 371 : 1854-1860, 2008.
 
5) Rainer TH, et al : Oral prednisolone in the treatment of acute gout : apragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 164 : 464-471, 2016.
 
6) Khanna D, et al : 2012 American College of Rheumatology guidelines for management of gout Part 2 : therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64 : 1447-1461, 2012.
PubMed
7) Zhang W, et al : EULAR evidence based recommendations for gout. Part II : Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 : 1312-1324, 2006.
PubMed
8) Schlesinger N, et al : Canakinumab for acute gouty arthritis in patients with limited treatment options : results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71 : 1839-1848, 2012.
PubMed
P.231 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編). メディカルレビュー社, 2010.
 
2) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia Nat Commun 3 : 764, 2012.
PubMed
3) Kumagai T, et al : Time to target uric acid to retard CKD progression. Clin Exp Nephrol, 2016. [Epub ahead of print].
 
4) Uchida S, et al : Targeting uric acid and the inhibition of progression to end-stage renal disease-a propensity score analysis. PLoS One 10 (12) : e0145506, 2015.
PubMed
5) Siu YP, et al : Use of allopurinol in slowing the progression of renal disease through its abihty to lower serum uric acid level. Am J Kidney Dis 47 : 51-59, 2006.
PubMed
6) Goicoechea M, et al : Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 (8) : 1388-1393, 2010.
PubMed
7) Goicoechea M, et al : Allopurinol and progression of CKD and cardiovascular events : long-term follow-up of a randomized clinical trial. Am J Kidney Dis 65 : 543-549, 2015.
PubMed
8) Bellomo G : The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression : a step forward. Am J Kidney Dis 65 (4) : 525-527, 2015.
PubMed
9) Perez-Ruiz F, et al : Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57 : 545-549, 1998.
 
10) Reinders MK, et al : Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26 : 1459-1465, 2007.
PubMed
11) Reinders MK, et al : Efficacy and tolerability of urate-lowering drugs in gout : a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68 : 51-56, 2009.
 
12) Jansen TL, et al : Benzbromarone withdrawn from the European market : another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 22 (5) : 651, 2004.
PubMed
13) 内田俊也 : 慢性腎臓病 (CKD) に合併する高尿酸血症に対するベンズブロマロンの臨床的有用性の検討. 医学と薬学 57 : 879-882, 2007.
Medical*Online
14) Fujimori S, et al : Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 30 : 1035-1038, 2011.
PubMed
P.238 掲載の参考文献
1) Robins RK : Potential purine antagonists. I. Synthesis of some 4, 6-substituted pyrazolo [3, 4-dl] pyrimidines. JAM Chem Soc 78 : 784-790, 1956.
 
2) Yue TF, Gutman AB : Effect of allopurinol (4-hydroxy-pyrazolo-3, 4-d pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 37 : 885-898, 1964.
 
3) Osada Y, et al : Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 241 (2-3) : 183-188, 1993.
PubMed
4) 高尿酸血症・痛風の治療ガイドライン (ガイドライン改訂委員会編), 第2版, メディカルレビュー社, 2010.
 
5) Hung SI, et al : HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102 (11) : 4134-4139, 2005.
PubMed
6) Yamamoto T, et al : Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Mod Rheumatol 25 (5) : 779-783, 2015.
PubMed
7) Hosoya T, et al : Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18 (6) : 876-884, 2014.
PubMed
P.243 掲載の参考文献
1) Davidson JN : Some properties of purified uricase. Biochem J 36 : 252-258, 1942.
PubMed
2) Masera G, et al : Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 100 : 152-155, 1982.
PubMed
3) Wassemann W, et al : Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoa/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82 : 160-165, 2003.
 
4) Pui CH, et al : Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11 (11) : 1813-1816, 1997.
PubMed
5) Coiffier B, et al : Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma : Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasbricase Activity in Adult Lymphoma) study. J Clin Oncol 21 : 4402-4406, 2003.
 
6) lshizawa K, et al : Safety and efficacy of rasburicase (SR29142) in a Japanes phase II study. Cancer Sci 100 : 357-362, 2008.
 
7) Cortes J, et al : Control of plasma uric acid in adults at risk for tumor lysis syndrome : efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol 28 : 4207-4213, 2010.
PubMed
8) Sundy JS, et al : Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 306 (7) : 711-720, 2011.
PubMed
9) Baraf HS, et al : Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol 20 : 427-432, 2014.
PubMed
10) Vadhan-Raj S, et al : A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23 : 1640-1645, 2012.
PubMed
11) Coutsouvelis J, et al : Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 75 : 550-553, 2012.
 
12) Jones GL, et al : Guideline for the management of tumor lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169 : 661-671, 2015.
 
P.249 掲載の参考文献
1) 辻裕ほか : 21年間の人間ドックデータからみる血清尿酸値および尿pHとメタボリックシンドローム関連諸因子との関係. 人間ドック 22 (3) : 383-388, 2007.
Medical*Online
2) Peters JP, Van Slyke DD : Quantitative Clinical Chemistry (2nd ed), p 949-977, Williams & Wilkins Co., Baltimore, 1946.
 
3) Shimizu T, et al : Novel evaluation of nephrolithiasis as a complication of gout : across-sectional study using helical computerized tomography. J Urol 189 (5) : 1747-1752, 2013.
 
4) Maejima I, et al : Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. Embo J 32 (17) : 2336-2347, 2013.
PubMed
5) 清水徹 : 尿アルカリ化薬. 高尿酸血症と痛風 9 (1) : 41-46, 2001.
Medical*Online
6) Berg C : Alkaline citrate in prevention of recurrent calcium oxalate stones. Scand J Urol Nephrol Suppl 130 : 1-83, 1990.
PubMed
7) Tiselius H, et al : Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7 (1) : 381-389 ; discussion 389-390, 1993.
 
8) 高橋和宏ほか : 早期腎障害患者に対する経口吸着炭素製剤 (クレメジン) と尿アルカリ化剤 (ウラリット) の併用効果について. Progress in Medicine 26 (4) : 897-902, 2006.
Medical*Online
9) Mahajan A, et al : Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78 (3) : 303-309, 2010.
PubMed
10) Saito J, et al : The alkalizer citrate reduces serum uric acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 35 (4) : 145-154, 2010.
PubMed
11) 鈴木正孝ほか : クエン酸カリウム・クエン酸ナトリウムの配合剤 (ウラリット-U) による夜間の筋痙攣の治療. Progress in Medicine 20 (6) : 1301-1303, 2000.
Medical*Online
P.255 掲載の参考文献
1) 尿酸降下薬の種類と選択. 高尿酸血症・痛風の治療ガイドライン, 第2版2012年追補版 (日本痛風・代謝学会ガイドライン改訂委員会編), p83-87, 2012.
 
2) 西野武士 : 日本発の「抗痛風剤のルネッサンス」. 痛風・核酸代謝学会誌 37 (2) : 77-92, 2016.
 
3) Atkinson DE : Energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry 7 (11) : 4030-4034, 1968.
 
4) Mateos FA, et al : Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage. J Clin Invest 79 (3) : 847-852, 1987.
 
5) Simmonds HA, et al : Hereditary xanthinuria. In : The Metabolic and Molecular Bases of Inherited Disease, 7th ed (ed by Scriver CR), p 1781-1797, McGraw-Hill, Health Professions Division, New York, London, 1995.
 
6) Elion GB : The purine path to chemotherapy. Science 244 : 41-47, 1989.
PubMed
7) Shimo T, et al : Xanthine crystals induced by topiroxostat, a xanthine o) ddoreductase inhibitor, in rats, cause transitional cell tumors. Arch Toxicol 88 (4) : 1035-1042, 2014.
 
8) Massey V, et al : On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo [3, 4-d] pyrimidines. J Biol Chem 245 : 2837-2844, 1970.
PubMed
9) Okamoto K et al : Mechanism of inhibition of xanthine oxidoreductase by allopurinol : crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol. Nucleosides Nucleotides Nucleic Acids 27 : 888-893, 2008.
PubMed
10) Okamoto K et al : An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278 : 1848-1855, 2003.
PubMed
11) Okamoto K et al : The crystal structure of xanthine oxidoreductase during catalysis : implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA 101 : 7931-7936, 2004.
PubMed
P.260 掲載の参考文献
1) Okuda C, et al : Serum CRP in patients with gout and effects of benzbromarone. Int J Clin Pharmacol Ther 49 : 191-197, 2011.
PubMed
2) Inokuchi T, et al : Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. Horm Metab Res 41 : 327-332, 2009.
PubMed
3) Ogino K, et al : Uric acid-lowering treatment with benzbromarone in patients with heart failure. Circ Heart Fail 3 : 73-81, 2010.
PubMed
4) Doehner W, Anker SD : Xanthine oxidase inhibition for chronic heart failure : is allopurinol the next therapeutic advance in heart failure? Heart 91 : 707-709, 2005.
PubMed
5) Baldwin W, et al : Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60 : 1258-1269, 2011.
 
6) Noman A, et al : Effects of high-dose allopurinol on exercise in patients with chronic stable angina : a randomized, placebo controlled crossover trial. Lancet 375 : 2161-2167, 2010.
PubMed
7) Goicoechea M, et al : Effects of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 (8) : 1388-1393, 2010.
PubMed
8) Thanassoulis G, et al : Gout, allopurinol use, and heart failure outcome. Arch Intern Med 170 : 1358-1364, 2010.
PubMed
9) Kamatani N, et al : An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthin oxidase, in patients with hyperuricemia including those with gout in Japan : phase 3 clinical study. J Clin Rheumatol 17 : S13-18, 2011.
PubMed
10) Hosoya T, et al : Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout : a phase 3, multicentre, randomized, double-bHnd, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther 41 : 290-297, 2016.
PubMed
11) Whelton A, et al : Renal function in gout : long-term treatment effects of febuxostat. J Clin Rheumatol 17 : 7-13, 2011.
PubMed
12) Sanchez-Lozada LG, et al : Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294 : F710-718, 2008.
PubMed
13) White WB, et al : Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J 164 : 14-20, 2012.
PubMed
14) Nakamura T, et al : Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice. Eur J Pharmacol 780 : 224-231, 2016.
PubMed
15) Kamijo-Ikemori A, et al : Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury. Am J Physiol Renal Physiol 310 : F1366-1376, 2016.
PubMed
P.267 掲載の参考文献
1) Tollner K et al : The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. Eur J Pharmacol 746 : 167-173, 2015.
PubMed
2) Shimodaira H, et al : Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J Clin Pharmacol 36 : 168-174, 1996.
PubMed
3) Takahashi H, et al : Potentiation of anticoagtilant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66 : 569-581, 1999.
PubMed
4) 高橋晴美ほか : ワルファリンとブコロームの相互作用機序の解明. 臨床薬理 29 : 267-268, 1998.
 
5) Gearry RB, et al : Azathiopurine and allopurinol : A two-edged interaction. J Gastroenterol Hepatol 25 : 653-655, 2010.
 
6) Knake C, et al : Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun 452 : 157-162, 2014.
PubMed
7) Mukoyoshi M, et al : In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase : plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 38 : 496-510, 2008.
PubMed
8) Khosravan R, et al : Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 46 : 855-866, 2006.
PubMed
9) Tsai M, et al : The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. Int J Clin Pharmacol Ther 50 : 331-337, 2012.
PubMed
10) Yamamoto T, et al : Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 50 : 631-633, 1991.
PubMed
11) Iwanaga T, et al : Involvement of uric acid transporters in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Disp 33 : 1791-1795, 2005.
 
12) Stocker SL, et al : Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 38 : 904-910, 2011.
 
13) Yamamoto T, et al : Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol 27 : 2232-2236, 2000.
 
14) Yamamoto T, et al : Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 28 : 2294-2297, 2001.
PubMed
15) Takahashi S, et al : Effects of combination treatment using anti-hyperuricaemic agents With fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 62 : 572-575, 2003.
PubMed
P.271 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2010.
 
2) 長瀬満夫ほか : Dual Energy CTにて多発性に関節, 靱帯や靱帯付着部に尿酸塩結晶を認めた痛風症例. Gout and Nucleic Acid Metabolism 37 (1) : 59, 2013.
 
P.276 掲載の参考文献
1) Zhang W, et al : EULAR evidence based recommendations for gout. Part II : management. report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 : 1312-1324, 2006.
PubMed
2) Khanna D, et al : 2012 American College of Rheumatology guidelines for management of gout. Part 2 : Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64 : 1447-1461, 2012.
PubMed
3) Zhu P, et al : Serum uric acid is associated with incident chronic kidney disease in middle-aged populations : a meta-analysis of 15 cohort studies. PLoS One 9 (6) : e100801, 2014.
PubMed
4) Johnson RJ, et al : Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41 : 1183-1190, 2003.
 
5) Wang H, et al : Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function : a meta-analysis. J Ren Nutr 23 (5) : 389-396, 2013.
PubMed
6) Grayson PC, et al : Hyperuricemia and incident hypertension : a systematic review and meta-analysis. Arthritis Care Res 63 : 102-110, 2011.
PubMed
7) Agarwal V, et al : Effect of allopurinol on blood pressure : a systematic reviews and meta-analysis. J Clin Hypertens 15 : 435-442, 2013.
 
8) Kim SY, et al : Hyperuricemia and coronary heart disease : a systematic review and meta-analysis. Arthritis Care Res 62 : 170-180, 2010.
PubMed
9) Kim SY, et al : Hyperuricemia and risk of stroke : a systematic review and meta-analysis. Arthritis Care Res 61 : 885-892, 2009.
 
10) Xu X, et al : Hyperuricemia is independently associated with increased risk of atrial fibrillation : A meta-analysis of cohort studies. Int J Cardiol 184 : 699-702, 2015.
PubMed
11) Kanbay M, et al : Effects of allopurinol on endothelial dysfunction : a meta-analysis. Am J Nephrol 39 (4) : 348-356, 2014.
PubMed
12) Hare JM, et al : Impact of oxypurinol in patients with symptomatic heart failure : results of the OPTCHF study. Am J Coll Cardiol 51 : 2301-2309, 2008.
 
13) Sui X, et al : Uric acid and the development of metabolic syndrome in women and men. Metabolism 57 : 845-852, 2007.
 
14) Tsunoda S, et al : Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients : effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 15 : 697-701, 2002.
 
15) Kodama S, et al : Association between serum uric acid and development of type 2 diabetes. Diabetes Care 32 : 1737-1742, 2009.
PubMed
16) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2010.
 
17) CKD診療ガイド 2013 (日本腎臓病学会編), 東京医学社, 2013.
 
P.281 掲載の参考文献
1) Aronson SJ, Rehm HL : Building the foundation for genomics in precision medicine. Nature 526 : 336-342, 2015.
PubMed
2) EpiPM Consonium : A roadmap for precision medicine in the epilepsies. Lancet Neurol 14 : 1219-1228, 2015.
PubMed
3) Kamatani N : Six-layer structure for genomics and its applications. J Hum Genet 61 : 267-270, 2016.
PubMed
4) 鎌谷直之 : ゲノミクスのための「六層構造」 : ゲノムデータを用いた研究検査, 治療を統合する強力な概念的フレームワーク. CLIN CALCIUM 26 : 73-79, 2016.
 
5) Welch EM, et al : PTC 124 targets genetic disorders caused by nonsense mutations. Nature 447 : 87-91, 2007.
PubMed
6) Fujiwara S, et al : Development and apPlication of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19 : 429-435, 2008.
 
7) Dite GS, et al : Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years : Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 25 : 359-365, 2016.
 
8) Chung WH, et al : Medical genetics : a marker for Stevens-Johnson syndrome. Nature 428 : 486, 2004.
PubMed
9) Hung SI, et al : HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102 : 4134-4139, 2005.
PubMed
10) Ozeki T, et al : Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20 : 1034-1041, 2011.
PubMed
11) Fong PC, et al : Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361 : 123-134, 2009.
PubMed
12) Mallal S, et al ; PREDICT-1 Study Team : HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358 : 568-579, 2008.
 
13) Chen P, et al ; Taiwan SJS Consortium : Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364 : 1126-1133, 2011.
PubMed
14) Kamatani N, et al : Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci USA 78 : 1219-1223, 1981.
PubMed
15) Pegram MD, et al : Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 : 2659-2671, 1998.
PubMed
16) Druker BJ, et al : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 : 1038-1042, 2001.
PubMed
17) Lynch TJ, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004.
PubMed
18) Kwak EL, et al : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 : 1693-1703, 2010.
PubMed
19) Soda M, et al : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 : 561-566, 2007.
PubMed
20) Antoniou AC, et al : The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91 : 1580-1590, 2004.
PubMed
P.286 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2010.
 
2) Hakoda M, et al : Serum uric acid concentration as a risk factor for cardiovascular mortality : a longterm cohort study of atomic bomb survivors. J Rheumatol 32 (5) : 906-912, 2005.
PubMed
3) Kamei K, et al : Serum uric acid levels and mortality in the Japanese population : the Yamagata (Takahata) study. Clin Exp Nephrol, 2016. [Epub ahead of print]
 
4) Odden MC, et al : Uric acid levels, kidney function, and cardiovascular mortality in US adults : National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis 64 (4) : 550-557, 2014.
PubMed
5) Braga F, et al : Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population : a systematic reView and meta-analysis. Clin Chem Lab Med 54 (1) : 7-15, 2016.
PubMed
6) Chen JH, et al : Attenuating the mortality risk of high serum uric acid : the role of physical activity underused. Ann Rheum Dis 74 (11) : 2034-2042, 2015.
PubMed
7) Kuo CF, et al : Effect of allopurinol on all-cause mortality in adults with incident gout : propensity score-matched landmark analysis. Rheumatology (Oxford) 54 (12) : 2145-2150, 2015.
PubMed
8) Kok VC, et al : Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes : a population-based matched-cohort study. PloS One 9 (6) : e99102, 2014.
 
P.292 掲載の参考文献
1) 高尿酸血症・痛風の生活指導. 高尿酸血症・痛風の治療ガイドライン, 第2版, p110-112, メディカルレビュー社, 2010.
 
2) Kaneko K, et al : Determination of purine contents of alcoholic beverages using High Performance Liquid Chromatography. Biomed Chromatogr 23 : 858-864, 2009.
PubMed
3) Fukuuchi T, et al : A simple HPLC method for determining the purine content of beer and beer-like alcoholic beverages. Anal Sci 29 : 511-517, 2013.
PubMed
4) Gibson T, et al : A controlled study of diet in patients with gout. Ann Rheum Dis 42 : 123-127, 1983.
 
5) Choi HK Curhan G : Beer, liquor, and wine consumption and serum uric acid level : the Third National Health and Nutrition Examination Survey. Arthritis Rheum 51 : 1023-1029, 2004.
PubMed
6) Faller J, Fox IH : Ethanol-induced hyperuricemia. Evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 307 : 1598-1602, 1982.
PubMed
7) Puig JG, Fox IH : Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate. J Clin Invest 74 : 936-941, 1984.
PubMed
8) Lieber CS, et al : Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 41 : 1863-1870, 1962.
 
9) Yamamoto T, et al : Effect of beer on the plasma concentration of uridine and purine bases. Metabolism 51 : 1317-1323, 2002.
PubMed
10) Nishioka K, et al : Influence of moderate drinking on purine and carbohydrate metabolism. Alcohl Clin Exp Res 26 : 20S-25S, 2002.
PubMed
11) Nakamura K et al : Alchol intake and the risk of hypemricaemia : a 6-year prospecdve study in Japanese men. Nutr Metab Cardiovasc Dis 22 : 989-996, 2012.
 
12) Wang M, et al : A meta-analysis of alcohol consumption and the risk of gout. Clin Rheumatol 32 : 1641-1648, 2013.
 
P.297 掲載の参考文献
1) Hall AP, et al : Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 42 : 27-37, 1967.
PubMed
2) Campion E, et al : Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82 : 421-426, 1987.
PubMed
3) Lin K, et al : The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27 : 1501-1505, 2000.
 
4) Janssens HJ, et al : Use of oral prednisolone or naproxen for the treatment of gout arthritis : a double -blind, randomised equivalence trial. Lancet 371 : 1854-1860, 2008.
 
5) Werlen D, et al : Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis : an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed 63 : 248-254, 1996.
PubMed
6) Fernaiidez C, et al : Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26 : 2285-2286, 1999.
 
7) Terkeltaub RA, et al : High versus low dosing of oral colchicine for early acute gout flare : Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62 : 1060-1068, 2010.
PubMed
8) 高尿酸血症・痛風の治療ガイドライン (第2版) (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2010.
 
9) Shoji A, et al : A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51 : 321-325, 2004.
PubMed
10) Becker MA, et al : Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36 : 1273-1282, 2009.
PubMed
11) Zhang W, et al : EULAR evidence based recommendations for gout. Part II : Management. Report of atask force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 : 1312-1324, 2006.
 
12) Khanna D, et al : 2012 American College of Rheumatology guidelines for management of gout. Part 1 : systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64 : 1431-1446, 2012.
PubMed
13) Khanna D, et al : 2012 American College of Rheumatology guidelines for management of gout. Part 2 : therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64 : 1447-1461, 2012.
PubMed
14) McGill NW, Dieppe PA : THE role of serum and synovial-fluid components in the promotion of urate crystal-formation. J Rheumatol 18 : 1042-1045, 1991.
PubMed
15) Perez-Ruiz F, et al : Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47 : 356-360, 2002.
 
P.302 掲載の参考文献
1) Mazzali M, et al : Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282 : 991-997, 2002.
 
2) Sanchez-Lozada LG, et al : Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283 : 1105-1110, 2002.
 
3) Johnson RJ, et al : Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41 : 1183-1190, 2003.
 
4) Price KL, et al : Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 17 : 1791-1795, 2006.
PubMed
5) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
6) Johnson RJ, et al : Uric acid and chronic kidney disease : which is chasing which? Nephrol Dial Transplant 28 : 2221-2228, 2013.
PubMed
7) Iseki K et al : Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44 : 642-650, 2004.
 
8) Toyama T, et al : Relationship between serum uric acid levels and chronic kidney disease in a Japanese cohort with normal or mildly reduced kidney function. PLoS One 10 : e0137449, 2015.
PubMed
9) Sonoda H, et al : Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33 : 352-357, 2011.
PubMed
10) Obermayr RP, et al : Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19 : 2407-2413, 2008.
 
11) Zhu P, et al : Serum uric acid is associated with incident chronic kidney disease in middle-aged populations : a meta-analysis of 15 cohort studies. PLoS One 9 : e100801, 2014.
PubMed
12) Kanbay M, et al : Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39 : 1227-1233, 2007.
PubMed
13) Siu YP, et al : Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47 : 51-59, 2006.
PubMed
14) Whelton A, et al : Preservation of renal function during gout treatment with febuxostat : a quantitative study. Postgrad Med 125 : 106-114, 2013.
PubMed
15) Tsuruta Y, et al : Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol 33 : 1643-1648, 2014.
PubMed
P.308 掲載の参考文献
1) Yasui T, et al : Prevalence and epidemiological characteristics of urolithiasis in Japan : national trends between 1965 and 2005. Urology 71 : 209-213, 2008.
PubMed
2) Shekarriz B, Stoller ML : Uric acid nephrolithiasis : current concepts and controversies. J Urol 168 : 1307-1314, 2002.
PubMed
3) 高尿酸血症・痛風の治療ガイドライン (第2版) (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p44-45, p 94-96, メディカルレビュー社, 2010.
 
4) Coe FL et al : Kidney stone disease. J Clin Invest 115 : 2598-2608, 2005.
 
5) 山口聡, 八竹直 : 尿酸代謝と尿路結石症. 痛風と核酸代謝 26 : 1-11, 2002.
 
6) Rodman JS, et al : Diagnosis and treatment of uric acid calculi. In : Kidney Stones : Medical and Surgical Management (ed by Coe FL, et al), p 980-982, Lippincott-Ravens Publishers, Philadelphia, 1996.
 
7) Moran ME, et al : Utility of oral dissolution therapy in the management of referred patients with secondarily treated uric acid stones. Urology 59 : 206-210, 2002.
PubMed
8) 尿路結石症診療ガイドライン (第1版) (日本泌尿器科学会ほか編), p53-72, 金原出版, 2002.
 
9) 尿路結石症診療ガイドライン 2013年版改訂委員会 : 尿路結石症診療ガイドライン (第2版) (日本泌尿器科学会ほか編), p119-120, 金原出版, 2013.
 
10) Pearle MS, et al : Medical management of kidney stones : AUA guideline. J Urol 192 : 316-324, 2014.
PubMed
11) European Association of Urology, Guidelines on Urolithiasis (2016). [http://uroweb.org/guideline/urolithiasis/]
 
12) Shimizu T, et al : Novel evaluation of nephrolithiasis as a complication of gout : a cross-sectional study using helical computerized tomography. J Urol 189 : 1747-1752, 2013.
 
13) 高橋哲, 伊藤俊英 : DSCTによる腹部の検査と診断. インナービジョン 24 : 85-89, 2009.
Medical*Online
14) Matsuo H, et al : Common defects of ABCG2, a high-capacity urate exporter, cause gout : a function-based genetic analysis in a Japanese population. Sci Transl Med 1 : 5ra11, 2009.
 
15) 山口聡ほか : 高尿酸血症を有する尿路結石症患者におけるABCG2遺伝子多型の検討. 日本尿路結石症学会誌 14 : 214-217, 2015.
 
P.315 掲載の参考文献
1) 津下一代ほか : 厚生労働科学研究「生活習慣病予防活動・疾病管理による健康指標に及ぼす影響と医療費適正化効果に関する研究」, 2014.
 
2) Battelli MG, et al : Xanthine oxidoreductase in atherosclerosis pathogenesis : Not only oxidative stress. Atherosclerosis 237 : 562-567, 2014.
PubMed
3) Berry CE, et al : Xanthine oxidoreductase and cardiovascular disease : molecular mechanisms and pathophysiological implications. J Physiol 555 : 589-606, 2004.
PubMed
4) Ives A, et al : Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. Nat Commun 6 : 6555, 2015.
 
5) Sanchez-Lozada LG, et al : Effects of febuxostat on metabolic and renal alteration in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294 : F710-F718, 2008.
PubMed
6) Cheung KJ, et al : Xanthine oxidoreductase is a regulator of adipogenesis and PPAR gamma activity. Cell Metab 5 : 115-128, 2007.
PubMed
7) Tsushima Y, et al : Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem 288 : 27138-27149, 2013.
 
8) Baldwin W, et al : Hyperuricemia as a mediator of the proiflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60 : 1258-1269, 2011.
 
9) Nomura J, et al : Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep 4 : 4554, 2014.
PubMed
10) Shirakura T, et al : Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 389 : 831-838, 2016.
PubMed
11) Nakatsu Y, et al : The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatotis in a rodent model. Am J Physiol Gastrointest Liver Physiol 309 : G42-G51, 2015.
 
12) Matsuo H, et al : Common defects of ABCG2, a high-capacity urate exporter, cause gout : A function-based genetic analysis in a Japanese population. Sci Transl Med 1 : 5-11, 2009.
 
P.322 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), p1-127, メディカルレビュー社, 2010.
 
2) 久留一郎 : 尿酸低下は心血管イベントを抑制するか? CORE Journal循環器 4 : 34-42, 2014.
Medical*Online
3) Kato M, et al : Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 96 (11) : 1576-1578, 2005.
PubMed
4) Tsutsui H, et al : Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 301 (6) : H2181-2190, 2011.
PubMed
5) Maharani N, et al : Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J 79 (12) : 2659-2668, 2015.
PubMed
6) Seet RC, et al : Is uric acid protective or deleterious in acute ischemic stroke? A prospective cohort study. Atherosclerosis 209 (1) : 215-219, 2010.
PubMed
7) Chamorro A, et al : Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS) : a randomised, double-blind phase 2b/3 trial. Lancet Neurol 13 (5) : 453-460, 2014.
PubMed
P.326 掲載の参考文献
1) Coiffier B, et al : Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. J Clin Oncol 26 : 2767-2778, 2008.
PubMed
2) Cairo MS, et al ; TLS Expert Panel : Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol 149 : 578-586, 2010.
 
3) Brereton HD, et al : Hyperphosphatemia and hypocalcemia in Burkitt lymophoma. Complications of chemotherapy. Arch Intern Med 135 : 307-309, 1975.
PubMed
4) Firwana BM, et al : Tumor lysis syndrome : a systematic reView of case series and case reports. Postgrad Med 124 : 92-101, 2012.
PubMed
5) Cohen LF, et al : Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 68 : 486-491, 1980.
PubMed
6) 腫瘍崩壊症候群 (TLS) 診療ガイダンス (日本臨床腫瘍学会編), 2013.
 
7) 稲井邦博ほか : 造血器疾患における高尿酸血症の病態. 痛風と核酸代謝 23 : 182-186, 1999.
 
8) 松田安史ほか : 著明な高尿酸血症, 腫瘍融解症候群を併発したBurkitt型急性リンパ性白血病. 痛風と核酸代謝 34 : 17-22, 2010.
 
9) Cammalleri L, Malaguarnera M : Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 4 : 83-93, 2007.
PubMed
10) Takai M, et al : Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies-a single institution's, pharmacokinetic and pilot prospective study. Anticancer Res 34 : 7287-7296, 2014.
PubMed
11) Takai M, et al : Reduced administration of rasburicase for tumor lysis syndrome : A single-institution experience. Oncol Lett 9 : 2119-2125, 2015.
PubMed
P.331 掲載の参考文献
1) 嶺尾郁夫 : メタボリックシンドロームにおける高尿酸血症の病態意義 歴史的経緯から最近の知見まで. Gout and Nucleic Acid Metabolism 32 : 121-132, 2008.
 
2) Salazar MR, et al : Optimal uric acid threshold to identify insulin resistance in healthy women. Metab Syndr Relat Disord 10 : 39-46, 2012.
PubMed
3) Tsunoda S, et al : Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients : effect of a low-energy diet and an insulin-sensitizing agents. Am J Hypertens 15 : 697-701, 2002.
 
4) Choi HK Ford ES : Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels-the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 47 : 713-717, 2008.
 
5) Bobulescu IA, Moe OW : Renal transport of uric acid : evolving concepts and uncertainties. Adv Chronic Kidney Dis 19 : 358-371, 2012.
 
6) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
7) Davies MJ, et al : Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 17 : 426-429, 2015.
PubMed
8) Zhu Y, et al : High uric acid directly inhibits insulin signaling and induces insulin resistance. Biochem Biophys Res Commun 447 : 707-714, 2014.
PubMed
9) Li Q, et al : Serum uric acid level and its association With metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 10 : 72, 2011.
PubMed
10) Mazzali M, et al : Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38 : 1101-1106, 2001.
PubMed
11) Smink PA, et al : An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection : a post-hoc analysis of the RENAAL and IDNT trials. JHypertens 30 : 1022-1028, 2012.
PubMed
12) Zoppini G, et al : Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 35 : 99-104, 2012.
PubMed
13) Hovind P, et al : Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes : An Inception Cohort Study. Diabetes 58 : 1668-1671, 2009.
PubMed
14) Wang L, et al : Use of Contrast-Enhanced Ultrasound to Study Relationship between Serum Uric Acid and Renal Microvascular Perfusion in Diabetic Kidney Disease. Biomed Res Int 2015 : 732317, 2015.
PubMed
15) Chang TH, et al : Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6 year cohort study. Diabetes Metab Res Rev 32 : 557-564, 2016.
 
P.334 掲載の参考文献
1) Janssens HJ, et al : A diagnostic rule for acute gouty artihritis in primary care without joint fluid analysis. Arch Intern Med 170 : 1120-1126, 2010.
PubMed
2) Margaretten ME, et al : Does this adult patients have septic arthritis? JAMA 297 : 1478-1488, 2007.
PubMed
3) Dubost JJ, et al : No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 61 : 267-269, 2002.
 
4) Kaandorp CT, et al : Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 38 : 1819-1825, 1995.
 
5) Pioro MH, Mandell BF : Septic arthritis [review]. Rheum Dis Clin North Am 23 : 239-258, 1997.
PubMed
6) Gilbert DN, et al : The Sanford guide to antimicrobial therapy, 2008, 3Sth edition, Antimicrobial Therapy, Inc, Sperryville, VA 2007.
 
7) Urano W, et al : The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 29 : 1950-1953, 2002.
PubMed
8) Yu KH, et al : Concomitant septic and gouty arthritis-an analysis of 30 cases. Rheumatol 42 : 1062-1066, 2003.
 
9) Martinot M, et al : Diagnostic value of serum and synovial procalcitonin in acute arthritis : prospective study of 42 patients. Clin Exp Rheumatol 23 : 303, 2005.
PubMed
10) Doi T, et al : Neutrophil CD64 expression as a diagnostic marker for local infection and crystal-induced arthritis. Mod Rheumatol 20 : 573, 2010.
PubMed
P.338 掲載の参考文献
1) 外反母趾診療ガイドライン 2014改訂第2版 (日本整形外科学会診療ガイドライン委員会, 外反母趾診療ガイドライン策定委員会編), 南江堂, 2014.
 
2) 生駒和也ほか : 外反母趾の診察・画像診断. MB Orthop 29 (4) : 17-23, 2016.
 
3) 高尿酸血症・痛風の治療ガイドライン 第2版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編), メディカルレビュー社, 2010.
 
4) 長瀬満夫, 布施泰子 : 痛風関節炎の診断. 整形・災害外科 56 (2) : 125-127, 2013.
 
P.343 掲載の参考文献
1) Kellgren JH, Lawrence JS : Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16 (4) : 494-502, 1957.
PubMed
2) Kulkarni K, et al : Obesity and osteoarthritis. Maturitas 89 : 22-28, 2016.
PubMed
3) Howard RG, et al : Presence of gout is associated with increased prevalence and severity of knee osteoarthritis among older men : results of a pilot study. J Clin Rheumatol 21 (2) : 63-71, 2015.
PubMed
4) Bevis M, et al : The association between gout and radiographic hand, knee and foot osteoarthritis : a cross-sectional study. BMC Musculoskelet Disord 17 (1) : 169, 2016,
PubMed
5) Thonar EJ, et al : Keratan sulfate in body fluids in joint disease. Acta Orthop Scand Suppl 266 : 103-106, 1995.
PubMed
6) Momohara S, et al : Cartilage oligomeric matrix protein in serum and synovial fluid of rheumatoid arthritis : potential use as a marker for joint cartilage damage. Mod Rheumatol 14 (5) : 356-360, 2004.
PubMed
7) Bellamy N, et al : Validation study of a computerized version of the Western Ontario and McMaster Universities VA3.0 Osteoarthritis Index. J Rheumatol 24 (12) : 2413-2415, 1997.
 
8) Akai M, et al : An outcome measure for Japanese people with knee osteoarthritis. J Rheumatol 32 (8) : 1524-1532, 2005.
PubMed
9) Hochberg MC, et al : American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64 (4) : 465-474, 2012.
PubMed
10) McAlindon TE, et al : OARS1 guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22 (3) : 363-388, 2014.
PubMed
11) Femandes L, et al : EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 72 (7) : 1125-1135, 2013.
 
P.348 掲載の参考文献
1) Zhang W, et al : European League Against Rheumatism (EULAR) recommendations for calcium pyrophosphate deposition. Part I : terminology and diagnosis. Ann Rheum Dis 70 : 563-570, 2011.
PubMed
2) Richette P, et al : An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 48 : 711-715, 2009.
PubMed
3) 緒方正光 : Calcium pyrophosphate dihydrate crystal deposition diseaseの臨床的研究. 日本整形外科学会雑誌 59 : 819, 1985.
Medical*Online
4) McCarty DJ : Calcium pyrophosphate dihydrate crystal deposition disease-1975. Arthritis Rheum 19 (Suppl 3) : 275-285, 1976.
 
5) Rosenthal AK : Pathogenesis of calcium pyrophosphate crystal deposition disease. Curr Rheumatol Rep 3 : 17-23, 2001.
PubMed
6) Masuda I, Ishikawa K : Clinical features of pseudogout attack. A survey of 50 cases. Clin Orthop Related Res 229 : 173-181, 1988.
 
7) Bilezikian JP, et al : Pseudogout after parathyrodectomy. Lancet 1 : 445-446, 1973.
 
8) Frediani B, et al : Diagnosis of calcium pyrophosphate dehydrate crystal deposition disease : Ultrasonographic criteria proposed. Ann Rheum Dis 64 : 638-640, 2005.
 
9) Zhang W, et al : EULAR recommendations for calcium pyrophosphate deposition. Part II : Management. Ann Rheum Dis 70 : 571-575, 2011.
PubMed
10) Chollet-Janin A, et al : Methothrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease : An exploratory analysis. Arthritis Rheum 56 : 688-692, 2007.
 
11) Finckh A, et al : Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease : no significant effect in a randomized crossover tria1. Arthritis Res Ther 16 : 458-465, 2015.
 
12) Ottaviani S, et al : Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis : a report of 16 cases and review of the literature. Joint Bone Spine 80 : 178-182, 2013.
PubMed
P.354 掲載の参考文献
1) 鈴木康夫 : 専門医の管理・治療が必要な疾患のガイドライン. 全身性疾患, 膠原病 19関節リウマチ. ガイドライン外来診療 2016 (泉 孝英編) p457-461, 日経メディカル開発, 2016.
 
2) Funovits J, et al : The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis : methodological report phase I. Ann Rheum Dis 69 : 1589-1595, 2010.
PubMed
3) Arnett FC, et al : The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 : 315-324, 1988.
PubMed
4) Smolen JS, et al : Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis 69 : 631-637, 2010.
PubMed
5) Aletaha D, et al : 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 : 2569-2581/Ann Rheum Dis 69 : 1580-1588, 2010.
 
6) 日本リウマチ学会新基準検証委員会 : ACR/EULAR新分類基準の検証について. [http://www.ryumachi-jp.com/info/news110913.pdf]
 
P.359 掲載の参考文献
1) Hench PS, Rosenberg EF : Palindromic rheumatism. A "new" of recurring disease of joints (arthritis, periarthritis, para-arthritis) apparendy producing no articula residues. Report of 34 cases ; its relation to "angioneural arthritis", "allergic rheumatism" and rheumatoid arthritis. Arch Intern Med 73 : 292-321, 1944.
 
2) Guerne PA, Weisman MH : Palindromic rheumatism : part of or apart from the spectrum of rheumatoid arthritis. Am J Med 93 : 451-460, 1992.
PubMed
3) Gonzalez-Lopez, et al : Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. J Rheumatol 26 (3) : 540-545, 1999.
PubMed
4) Sanmarti R, et al : Palindromic rheumatism and other relapsing arthritis. Best Pract Res Chn Rheumatol 18 (5) : 647-661, 2004.
 
5) Schreiber S, et al : Palindromic rheumatism with rheumatoid nodules : acase report with ultrastructual studies. Ann Rheum Dis 45 : 78-81, 1986.
 
6) Hannonen P, et al : Palindromic rheumatism. A clinical survey of sixty patients. Scad J Rheumatol 16 (6) : 413-420, 1987.
 
7) Salvador G, et al : Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 42 : 972-975, 2003.
PubMed
8) Maksymowych WP, et al : HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 29 (11) : 2319-2326, 2002.
PubMed
9) Koskinen E, et al : Palindromic rheumatism : longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 36 (9) : 1873-1875, 2009.
PubMed

IV 低尿酸血症の臨床

P.367 掲載の参考文献
1) Bairaktari ET, et al : Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 41 : 1225-1232, 2003.
 
2) Wang S, et al : Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology 16 : 767-776, 2011.
 
3) Wakasugi M, et al : Association between hypouricemia and reduced kidney function : across-sectional population-based study in Japan. Am J Nephrol 41 : 138-146, 2015.
 
4) Lee JH, et al : Prevalence of hypouricaemia and SLC22A12 mutations in healthy Korean subjects. Nephrology 13 : 661-666, 2008.
PubMed
5) Ichida K, et al : Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 74 : 243-251, 2008.
PubMed
6) Ogino K, et al : Clinical significance of hypouricemia in hospitalized patients. J Med 22 : 76-82, 1991.
PubMed
7) 田部晃 : 低尿酸血症の病態についての研究. 東京慈恵会医科大学雑誌 111 : 821-839, 1996.
Medical*Online
8) Gresser U, et al : Uric acid levels in southern Germany in 1989. A comparison with studies from 1962, 1971, and 1984. Klin Wochenschr 68 : 1222-1228, 1990.
PubMed
9) Iwai N, et al : A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 66 : 935-944, 2004.
PubMed
10) Tanigtichi A, et al : A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 52 : 2576-2577, 2005.
 
11) Ichida K, et al : Clinical and molecular analysis of patients with renal hypouricemia in Japan-infiuence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 : 164-173, 2004.
 
12) Gabrikova D, et al : High frequency of SLC22A12 variants causing renal hypouricemia 1 in the Czech and Slovak Roma population ; simple and rapid detection method by allele-specific polymerase chain reaction. Urolithiasis 43 : 441-445, 2015.
PubMed
13) Hisatome I, et al : Cause of persistent hypouricemia in outpatients. Nephron 51 : 13-16, 1989.
PubMed
14) Tabara Y, et al : Association of four genetic loci with uric acid levels and reduced renal function : the J-SHIPP Suita study. Am J Nephrol 32 : 279-286, 2010.
 
15) Kanda E, et al : Uric acid level has a U-shaped association with loss of kidney function in healthy people : a prospective cohort study. PloS One 10 : eO118031, 2015.
 
P.372 掲載の参考文献
1) 松尾洋孝, 市田公美 : 症例検討 症例を読む (第29回) GLUT9の異常症. 高尿酸血症と痛風 18 : 84-89, 2010.
 
2) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
3) Matsuo H, et al : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83 : 744-751, 2008.
PubMed
4) Matsuo H, et al : Common defects of ABCG2, a high-capacity urate exporter, cause gout : a function-based genetic analysis in a Japanese population. Sci Transl Med 1 : 5ra11, 2009.
 
5) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
6) Kawamura Y, et al : Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides Nucleic Acids 30 : 1105-1111, 2011.
PubMed
7) 松尾洋孝 : 尿酸の再吸収機構と輸送体病 ゲノムワイド関連解析後の新展開. Annual Review腎臓 2010 : 9-20, 2010.
 
8) Ichida K, et al : Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 : 164-173, 2004.
PubMed
9) Sakiyama M, et al : The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep 6 : 20148, 2016.
PubMed
10) Chiba T, et al : Identification of a hypouricemia patient with SLC2A9 R380W, a pathogenic mutation for renal hypouricemia type 2. Nucleosides Nucleotides Nucleic Acids 33 : 261-265, 2014.
PubMed
11) 松尾洋孝, 四ノ宮成祥 : 腎性低尿酸血症の遺伝学. Annual Review糖尿病・代謝・内分泌 2012 : 145-154, 2012.
Medical*Online
12) Dent CE, Philpot GR : Xanthinuria, an inborn error (or deviation) of metabolism. Lancet 266 : 182-185, 1954.
PubMed
13) Ichida K, et al : Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest 99 : 2391-2397, 1997.
PubMed
14) 市田公美 : 日本が貢献した世界的新知見 キサンチン尿症の遺伝子異常. 高尿酸血症と痛風 21 : 54-61, 2013.
 
15) Ichida K, et al : Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun 282 : 1194-1200, 2001.
PubMed
P.376 掲載の参考文献
1) Ames BN, et al : Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer : a hypothesis. Proc Natl Acad Sci USA 78 : 6858-6862, 1981.
PubMed
2) Ichida K et al : Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 : 164-173, 2004.
PubMed
3) Ishikawa I : Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia. Nephron 91 : 559-570, 2002.
PubMed
4) Ishikawa I, et al : Acute renal failure with severe loin pain and patchy renal vasoconstriction. In : Acute Renal Failure (ed by Eliahou HE), p 224-229, John Libbey & Company Ltd, London, 1982.
 
5) Ishikawa I : Exercise-Induced Acute Renal Failure-Acute Renal Failure with Severe Loin Pain and Patchy Renal lschemia after Anaerobic Exercise, p 1-108, Springer Japan, Tokyo, 2007.
 
6) 石川勲 : 運動後急性腎不全 (ALPE), p 1-65, 金沢医科大学出版局, 2006.
 
7) Ishikawa I, et al : Exercise-induced acute renal failure in 3 patients with renal hypouricemia. Nippon Jinzo Gakkai Shi 32 : 923-928, 1990.
PubMed
8) 石川勲 : 運動後の急性腎障害. 日本内科学会雑誌 103 : 1101-1107, 2014.
 
9) Ishikawa I, et al : EVidence for patchy renal vasoconstriction in man : observation by CT scan. Nephron 27 : 31-34, 1981.
PubMed
10) 石川勲 : リスクファクターとしての低尿酸血症. 高尿酸血症と痛風 18 : 59-66, 2010.
Medical*Online
11) Kaneko K : et al : OXidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol 24 : 869-871, 2009.
PubMed
12) Kamei K : et al : Acute kidney injury after acute gastroenteritis in an infant With hereditary hypouricemia. Eur J Pediatr 173 : 247-249, 2014.
 
13) Takeda Y, et al : Two cases of nephrotic syndrome (NS) -induced acute kidney injury (AKI) associated with renal hypouricemia. Clin Nephrol 76 : 78-82, 2011.
PubMed
14) Wakasugi M, et al : Association between hypouricemia and reduced kidney function : a cross-sectional population-based study in Japan. Am J Nephrol 41 : 138-146, 2015.
PubMed
15) Otomo K, et al : Serum uric acid level as a risk factor for acute kidney injury in hospitalized patients : a retrospective database analysis using the integrated medical information system at Kochi Medical School hospital. Clin Exp Nephrol 20 : 235-243, 2016.
PubMed
P.381 掲載の参考文献
1) Praetorius E, Kirk JE : Hypouricemia : with evidence for tubular elimination of uric acid. J Lab Clin Med 35 : 865-868, 1950.
PubMed
2) Akaoka I, et al : Familial hypouricaemia due to renal tubular defect of urate transport. Ann Clin Res 7 : 318-324, 1975.
PubMed
3) Suzuki T, et al : Genetic heterogeneity of familial hypouricemia due to isolated renal tubular defect. Jinrui Idengaku Zasshi 26 : 243-248, 1981.
PubMed
4) Enomoto A, et al : Molecular identhication of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
5) Matsuo H, et al : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83 : 744-751, 2008.
PubMed
6) Sakiyama M, et al : The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep 6 : 20148, 2016.
PubMed
7) Dinour D, et al : Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 21 : 64-72, 2010.
PubMed
8) 松尾洋孝ほか : 尿酸動態の支配要因としての尿酸トランスポーター. 細胞工学 31 : 553-557, 2012.
 
9) Kawamura Y, et al : Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides Nucleic Acids 30 : 1105-1111, 2011.
PubMed
10) 松尾洋孝, 四ノ宮成祥 : 腎性低尿酸血症の遺伝学. Annual Review糖尿病・代謝・内分泌 2012 : 145-154, 2012.
Medical*Online
11) Ishikawa I : Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia. Nephron 91 : 559-570, 2002.
PubMed
12) Kikuchi Y, et al : Patients with renal hypouricemia with exercise-induced acute renal failure and chronic renal dysfunction. Clin Nephrol 53 : 467-472, 2000.
PubMed
13) Ichida K, et al : Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 : 164-173, 2004.
PubMed
14) 四ノ宮成祥 : 腎性低尿酸血症の全国的実態把握厚生労働科学研究費補助金 (難治性疾患等克服研究事業) 総合報告書, 2013.
 
15) 浜田紀宏 : 生体内における尿酸の役割 心臓・高血圧に対する尿酸の影響. 痛風と核酸代謝 38 : 150-152, 2014.
 
16) 山口聡, 八竹直 : 尿酸代謝と尿路結石症. 痛風と核酸代謝 26 : 1-11, 2002.
 
17) 石川勲 : 運動後急性腎不全 (ALPE). 痛風と核酸代謝 34 : 145-157, 2010.
 
18) 市田公美 : 遺伝性低尿酸血症. 日本腎臓学会誌 53 : 142-145, 2011.
 
19) Yeun JY, Hasbargen JA : Renal hypouricemia : prevention of exercise-induced acute renal failure and a review of the literature. Am J Kidney Dis 25 : 937-946, 1995.
 
20) Bhasin B, et al : Hereditary renal hypouricemia : a new role for allopurinol? Am J Med 127 : e3-4, 2014.
PubMed
P.385 掲載の参考文献
1) Schwarz G, et al : Molybdenum cofactors, enzymes and pathways. Nature 460 : 839-847, 2009.
PubMed
2) Mendel RR : The molybdenum cofactor. J Biol Chem 288 : 13165-13172, 2013.
PubMed
3) Hille R : The Mononuclear Molybdenum Enzymes. Chem Rev 96 : 2757-2816, 1996.
PubMed
4) Hille R, et al : The mononuclear molybdenum enzymes. Chem Rev 114 : 3963-4038, 2014.
PubMed
5) Nishino T, et al : Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 275 : 3278-3289, 2008.
PubMed
6) Nishino T, et al : The C-terminal peptide plays a role in the fbrmation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase. FEBS J 282 : 3075-3090, 2015.
 
7) Nishino T : The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury. J Biochem 116 : 1-6, 1994.
PubMed
8) Vorbach C, et al : The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion : gene sharing in the lactating mammary gland, Genes Dev 16 : 3223-3235, 2002.
PubMed
9) Simmonds HA, et al : Hereditary xanthinuria. In : The Metabolic and Molecular Bases of Inherited Disease, 7th ed (ed by Scriver CR), p 1781-1797, McGraw-Hill, Health Professions Division, New York ; London, 1995.
 
10) Dent CE, Philpot GR : Xanthinuria, an inborn error (or deviation) of metabolism. Lancet 266 : 182-185, 1954.
PubMed
11) Ichida K et al : Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun 282 : 1194-1200, 2001.
PubMed
12) Duran M, et al : Combined deficiency of xanthine oxidase and sulphite oxidase : a defect of molybdenum metabolism or transport. J Inherit Metab Dis 1 : 175-178, 1978.
 
13) Wadman SK, et al : Absence of hepatic molybdenum cofactor : an inborn error of metabolism leading to a combined deficiency of sulphite oxidase and xanthine dehydrogenase. J Inherit Metab Dis 6 (Suppl 1) : 78-83, 1983.
 
P.390 掲載の参考文献
1) Walker PL, et al : Purine nucleoside phosphorylase deficiency : a mutation update. Nucleoside Nucleptides Nucleic Acids 30 : 1243-1247, 2011.
PubMed
2) Markert ML : Purine nucleoside phosphorylase deficiency. Immunodefic Rev 3 (1) : 45-81, 1991.
PubMed
3) Hershfield MS, Mitchell BS : Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In : The Metabolic & Molecular Basis of Inherited Disease, 8th ed (ed by Scriber CR, et al), p 2585-2642, McGraw-Hill, New York 2001.
 
4) Sasaki Y, et al : Direct evidence of autosomal recessive inheritance of Arg24 to termination codon in purine nucleoside phosphorylase gene in a family with a severe combined immunodeficiency patient Hum Genet 103 (1) : 81-85, 1998.
 
5) Yamamoto T, et al : High IL-18 (interferon-gamma inducing factor) concentration in a purine nucleoside phosphorylase deficient patient. Arch Dis Child 81 (2) : 179-180, 1999.
 
6) Bzowska A, et al : Purine nucleoside phosphorylases : properties, functions, and clinical aspects. Pharmacol Ther 88 (3) : 349-425, 2000.
PubMed
P.395 掲載の参考文献
1) 川杉要, 竹内二士夫 : 5-ホスホリボシル-1-ピロリン酸 (PRPP) 合成酵素. 日本臨牀 61 (増刊号 1) : 20-23, 2003.
 
2) 川杉要, 竹内二士夫 : PRPP合成酵素欠損症. 日本臨牀 61 (増刊号 1) : 383-385, 2003.
 
3) Wada Y, et al : Hypouricemic, mentally retarded infant With a defect of 5-phosphoribosyl-1-pyrophosphate synthetase of erythrocytes. Tohoku J Exp Med 113 : 149-157, 1974.
PubMed
4) 今枝弘美ほか : ホスホリボシルピロリン酸合成酵素欠損症. 別冊日本臨牀 ・先天代謝異常症候群 (上), p435-439, 日本臨牀社, 1998.
 
5) 和田義郎 : ホスホリボシルピロリン酸合成酵素欠損症. Molecular Medicine 32 : 214-215, 1995.
 
6) 山田裕一 : PRPP合成酵素遺伝子PRPS1の遺伝子異常に起因する4つの症候群. 痛風と核酸代謝 36 (1) : 1-8, 2012.
 
7) Synofzik M, et al : X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum : evidence from a family with a novel PRPS1 mutation. Orphanet J Rare Dis 9 : 24, 2014.
 
8) de Bourwer APM, et al : Arts syndrome is caused by loss-of-function mutations in PRPS1. Am J Hum Genet 81 (3) : 507-518, 2007.
 
9) Kim HJ, et al : Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). Am J Hum Genet 81 (3) : 552-558, 2007.
PubMed
10) Liu X, et al : Loss-of-function mutations in the PRPS1 gene cause a type of nonsyndromic X-linked sensorineural deafhess, DFN2. Am J Hum Genet 86 (1) : 65-71, 2010.
 
P.399 掲載の参考文献
1) Bobulescu IA, Moe OW : Renal transport of uric acid : evolving concepts and uncertainties. Adv Chronic Kidney Dis 19 : 358-371, 2012.
 
2) Fathallah-Shaykh SA, Cramer MT : Uric acid and the kidney. Pediatr Nephrol 29 : 999-1008, 2014.
PubMed
3) Igarashi T : Pediatric Fanconi syndrome. In : Pediatric Nephrology (ed by Ellis DA, et al), p 1355-1388, Springer Reference, 2016.
 
4) Sekine T, et al : Japanese Dent disease has a wider clinical spectrum than Dent disease in Europe/USA : genetic and clinical studies of 86 unrelated patients With low-molecular-weight proteinuria. Nephrol Dial Transplant 29 : 376-384, 2014.
 
5) Lewis RA, et al : Lowe Syndrome. In : Gene Reviews (ed by Pagon RA, et al), University of Washington, Seattle, 2012.
 
6) Watanabe T, et al : Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 20 : 814-817, 2005.
PubMed
7) 三浦健一郎 : Fanconi症候群/Lowe症候群. 腎と透析 74増 : 290-292, 2013.
 
P.403 掲載の参考文献
1) Dorhout Mees EJ, et al : Elevation of uric aicd clearance caused by inappropriate antidiuretic hormone secretion. Acta Med Scand 189 (1-2) : 69-72, 1971.
 
2) 藏城雅文 : 諸領域の疾患における高尿酸血症とその病態・治療 各種内分泌疾患の尿酸代謝への影響. 痛風と核酸代謝 36 (2) : 143, 2012.
 
3) Shichiri M, et al : Renal handling of urate in the syndrome of inappropriate secretion of antidiuretic hormone. Arch Intern Med 145 (11) : 2045-2047, 1985.
PubMed
4) Adamopoulos D, et al : The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh) 85 (1) : 198-208, 1977.
PubMed
5) Yahyaoui R. et al : Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab 93 (6) : 2230-2233, 2008.
 
6) Semple PF, et al : Serial studies of the renal clearance of urate and inulin during pregnancy and after the puerperium in normal women. Clin Sci Mol Med 47 (6) : 559-565, 1974.
PubMed
7) Kailajarvi M, et al : Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res 20 (2B) : 1323-1327, 2000.
 
8) Atallah AN, et al : Progesterone increases glomerular filtration rate, urinary kallikrein excretion and uric acid clearance in normal women. Braz J Med Biol Res 21 (1) : 71-74, 1988.
PubMed
9) Takiue Y, et al : The effect of female hormones upon urate transport systems in the mouse kidney. Nucleosides Nucleotides Nucleic Acids 30 (2) : 113-119, 2011.
PubMed
10) Hosoyamada M, et al : The effect of testosterone upon the urate reabsorptive transport system in mouse kidney. Nucleosides Nucleotides Nucleic Acids 29 (7) : 574-579, 2010.
PubMed
11) Darlington LG, et al : Changes in urate metabolism after castration of patients suffering from carcinoma of the prostate. Adv Exp Med Biol 309A : 235-238, 1991.
PubMed
12) 森脇優司 : 高尿酸血症・低尿酸血症 痛風の治療新ガイドライン 低尿酸血症の臨床 二次性 (続発性) 低尿酸血症 肝疾患と低尿酸血症. 日本臨牀 61 (増刊号 1) : 398-402, 2003.
 
13) Saito I, et al : Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 26 (6) : 241-247, 1978.
PubMed
14) 南場雅ほか : 原発性アルドステロン症患者における尿酸代謝の検討. 日本内分泌学会雑誌 68 (1) : 51-61, 1992.
Medical*Online
15) Raff H : Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 252 (4 Pt 2) : R635-644, 1987.
 
P.411 掲載の参考文献
1) 藤森新 : 低尿酸血症の定義と病因別分類. 日本臨牀 61 (増刊号 1) : 353-356, 2003.
 
2) 今村信ほか : 二次性 (続発性) 低尿酸血症 悪性腫瘍. 日本臨牀 61 (増刊号 1) : 393-397, 2003.
 
3) Dwosh IL, et al : Hypouricemia in disease : A study of different mechanisms. J Lab Clin Med 90 : 153-161, 1977.
PubMed
4) Rieselbach RE, et al : Influence of the kidney upon urate homeostasis in health and disease. Am J Med 56 : 665-675, 1974.
PubMed
5) Sorensen JB, et al : Hypouricemia and urate excretion in small cell lung carcinoma patients with syndrome of inappropriate antidiureuresis. Acta Oncol 27 : 351-355, 1988.
PubMed
6) Passamonte PM : Hypouricemia, inappropriate secretion of antidiuretic hormone, and small cell carcinoma of the lung. Arch Intern Med 144 : 1569-1570, 1984.
PubMed
7) Maesaka JK, et al : Hyponatremia and hypouricemia : differentiation from SIADH. Clin Nephrol 33 : 174-178, 1990.
PubMed
8) Magoula I, et al : Hypouricemia in liver cell carcinoma : an isolated renal tubular defect. Am J Med 83 : 196-197, 1987.
PubMed
9) 森脇優司ほか : 低尿酸血症をきたした原発性肝癌の1例. 日本内科学会雑誌 75 : 1769-1773, 1986.
 
10) Puig JG, et al : Hypouricemia and medullary carcinoma of the thyroid. Adv Exp Med Biol 165 : 211-213, 1984.
PubMed
11) Morales M, Garcia-Nieto V : Hypouricemia and cancer. A study of mechanisms of renal urate wasting in two cases. Oncology 53 : 345-348, 1996.
 
12) Torimoto K, et al : A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocrine J 59 : 1051-1056, 2012.
 
13) Yoshioka K et al : Development of severe hyponatremia due to salt-losing nephropathy after esophagectomy for esophageal cancer. Case Rep Med Article ID 241283 : 1-4, 2009.
 
14) Ramsdell CM, Kekkey WN : The clinical significance of hypouricemia. Ann Intern Med 78 : 239-242, 1973.
 
15) Mia MA, Delamore IW : Hypouricemia and proximal renal tubular dysfunction in acute myeloid leukemia. Brit Med J 3 : 775-777, 1974.
 
16) 田中経雄ほか : 急性白血病における低尿酸血症の検討. プリン・ピリミジン代謝1 6 : 160-165, 1992.
 
17) 岡陽子ほか : 造血器腫瘍と尿酸代謝. 痛風と核酸代謝 33 : 99, 2009.
 
18) 小嶋千明ほか : 小児急性白血病患'者の治療各時期における血清尿酸値の検討. 痛風と核酸代謝 36 : 105-112, 2012.
 
19) 19) Elisaf MS : Hypokalemia, hypophosphatemia and hypouricemia due to proximal renal tubular dysfunction in acute myeloid leukemia. Eur J Haematol 64 : 277-278, 2000.
 
20) 高木和貴ほか : 悪性リンパ腫におけるCHOP療法後早期の尿酸動態. 痛風と核酸代謝 27 : 11-18, 2003.
 
21) Bennett JS, et al : Hypouricemia in Hodgkin's disease. Ann Intern Med 76 : 751-756, 1972.
PubMed
22) Zomkoff K, et al : Hypouricemia in Hodgkin's disease. N Y State J Med 78 : 1047-1049, 1978.
 
23) Tykarski A : Mechanism of hypouricemia in Hodgkin's disease. Isolated defect in postsecretory reabsorption of uric acid. Nephron 50 : 217-219, 1988.
PubMed
24) 木下圭一ほか : 骨髄異形成症候群の1例に認められた低尿酸血症の解析. プリン・ピリミジン代謝 22 : 66, 1998.
 
25) 塩宏 : 悪性リンパ腫と多発性骨髄腫患者における血清尿酸値. 尿酸 8 : 188-192, 1984.
 
26) Uchida S, et al : Adult Fanconi syndrome secondary to kappa-light chain myeloma : improvement of tubular functions after treatment for myeloma. Nephron 55 : 332-335, 1990.
PubMed
27) Liamis G, et al : Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol 777 : 78-87, 2016.
PubMed
28) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
29) Esparza N, et al : Hypouricemia and tubular transport of uric acid. Nefrologia 31 : 44-50, 2011.
 
30) Mao Q, Unadkat JD : Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J 17 : 65-82, 2015.
PubMed
P.417 掲載の参考文献
1) Ogino K, et al : Clinical significance of hypouricemia in hospitalized patients. J Med 22 : 76-82, 1991.
PubMed
2) Hisatome I, et al : Cause of persistent hypouricemia in outpatients. Nephron 51 : 13-16, 1989.
PubMed
3) 久留一郎, 重政千秋 : 心・血管障害の危険因子としての高尿酸血症. Mebio 17 : 60-69, 2000.
 
4) Anzai N, Endou H : Urate transporters : an evolving field. Semin Nephrol 31 : 400-409, 2011.
PubMed
5) Enomoto A, et al : Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
6) Anzai N, et al : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283 : 26834-26838, 2008.
PubMed
7) 水田栄之助, 久留一郎 : 高尿酸血症からアプローチする生活習慣病の治療 : 高尿酸血症とメタボリックシンドローム : 病態と治療 日本医事新報 4787 : 33-40, 2016.
 
8) 日本痛風・核酸代謝学ガイドライン改訂委員会 : 3章 ; 合併症, 併発症に対する治療. 高尿酸血症・痛風の治療ガイドライン (第2版), p97-100, メディカルレビュー社, 2010.
 
9) Uetake D, et al : Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 49 : 89-94, 2010.
PubMed
10) Athyros VG, et al : GREACE Study Collaborative Group : Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease : apost hoc analysis of the GREACE study. Arch Med Sci 9 : 418-426, 2013.
 
11) Chino Y, et al : SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35 : 391-404, 2014.
PubMed
12) Hisatome I, et al : Effect of prednisolone on urate and oxypurine excretion. Horm Metab Res 23 : 513-514, 1991.
PubMed
13) Hisatome I, et al : Renal hypouricemia with both drug-insensitive secretion and defective reabsorption of urate : A novel type of renal hypouricemia. Nephron 64 : 447-451, 1993.
PubMed
14) Ohtahara A, et al : The release of the substrate of xanthine oxidase in hypertensive patients was suppressed by ACE inhibitor and alpha-1 blocker. J Hypertens 19 : 575-582, 2001.
 
15) Miyazaki S, et al : Effects of azelnidipine on uric acid metabolism in patients With essential hypertension. Clin Exp Hypertens 36 : 447-453, 2014.
PubMed

V 特論

P.425 掲載の参考文献
1) Nakashima M, et al : Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42 : 333-335, 1992.
PubMed
2) Soffer BA, et al : Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26 : 112-117, 1995.
PubMed
3) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 : 995-1003, 2002.
PubMed
4) Hoieggen A, et al : The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 : 1041-1049, 2004.
PubMed
5) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
6) Miao Y, et al : Effect of a reduction in uric acid on renal outcomes during losartan treatment : a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58 : 2-7, 2011.
PubMed
7) Roch-Ramel F, et al : Urate transport in brush-border membrane of human kidney. Am J Physiol 266 : F797-805, 1994.
PubMed
8) Roch-Ramel F, et al : Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280 : 839-845, 1997.
PubMed
9) Iwanaga T, et al : Concentratiordependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320 : 211-217, 2007.
PubMed
10) Hamada T, et al : Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21 : 1157-1162, 2008.
PubMed
11) Sun H, et al : URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics 16 : 855-863, 2015.
PubMed
12) Sweet CS, et al : Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 7 : 1035-1040, 1994.
PubMed
13) Bumier M, et al : Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22 : 339-347, 1993.
 
14) Nakamura M, et al : Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci 114 : 115-118, 2010.
PubMed
15) Perlstein TS, et al : Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 66 : 1465-1470, 2004.
PubMed
16) Talaat KM, El-Sheikh AR : The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 27 : 435-440, 2007.
PubMed
17) Ohashi N, et al : Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms. Nephrology (Carlton) 20 : 814-819, 2015.
PubMed
18) Mazzali M, et al : Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38 : 1101-1106, 2001.
PubMed
19) Kim YG, et al : Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med 6 : 837-848, 2000.
PubMed
20) Mazzali M, et al : Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol 282 : F991-997, 2002.
PubMed
21) Kang DH, et al : Arole for uric acid in the progression of renal disease. J Am Soc Nephrol 13 : 2888-2897, 2002.
 
22) Gilbert RE, et al : Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 155 : 429-440, 1999.
PubMed
23) Chen M, et al : Renin and renin mRNA in proximal tubules of the rat kidney. J Clin Invest 94 : 237-243, 1994.
 
24) Ingelfinger JR et al : In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85 : 417-423, 1990.
PubMed
25) Corry DB, et al : Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26 : 269-275, 2008.
PubMed
26) YU MA, et al : Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28 : 1234-1242, 2010.
PubMed
27) Zhang JX, et al : Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-LI adipocytes. Endocrine 48 : 135-142, 2015.
 
28) Watanabe S, et al : Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40 : 355-360, 2002.
PubMed
29) Kanellis J, et al : Uric acid stirnulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41 : 1287-1293, 2003.
PubMed
P.429 掲載の参考文献
1) Yamamoto T, et al : Effect of beer on the plasma concentrations of uridine and purine bases. Metabolism 51 : 1317-1323, 2002.
PubMed
2) Gibson T, et al : A controlled study of diet pationts with gout. Ann Rheum Dis 42 : 123-127, 1983.
 
3) Choi HK Curban G : Beer, liquor, and wine consumption and serum uric acid level : The Third National Health and Nutrition Examination Survey. Arthritis Rheum 51 : 1023-1029, 2004.
 
4) Yamamoto T, et al : Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 356 : 35-57, 2005.
PubMed
5) Yamamoto T, et al : Effect of ethanol and fructose on plasma uridine and purin bases. Metabolism 46 : 544-547, 1997.
PubMed
6) 山本徹也 : ショ糖, 果物摂取と高尿酸血症. 高尿酸血症と痛風 16 : 42-45, 2008.
Medical*Online
7) Ohno M, et al : Effects of exercise and grape juice ingestion in combination on plasma concentrations of purin bases and uridine. Clin Chim Acta 388 : 167-172, 2008.
PubMed
P.434 掲載の参考文献
1) 金井好克 : 総論 薬効標的のトランスポーター. 遺伝子MOOK 12 最新トランスポーター研究 2009 (杉山雄一ほか編), p29-34, メディカルドゥ, 2009.
 
2) 安西尚彦ほか : 腎臓の有機溶質・薬物トランスポーター. 第6回グルコーストランスポーター SLC2, SLC5. 高尿酸血症と痛風 18 : 78-82, 2010.
 
3) 安西尚彦 : 膜輸送蛋白質Up-to-Date. 日本腎臓学会誌 50 : 110-113, 2008.
 
4) 安西尚彦, 遠藤仁 : 腎尿酸トランスポーターと血清尿酸値異常. 医学のあゆみ 216 : 685-691, 2006.
Medical*Online
5) 安西尚彦 : 腎の尿酸輸送とトランスポーター. 綜合臨牀 59 : 190-194, 2010.
Medical*Online
6) Enomoto A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
7) Anzai N, et al : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283 : 26834-26838, 2008.
PubMed
8) Kamatani Y, et al : Genome-Wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 42 : 210-215, 2010.
 
9) Choi HK, Ford ES : Haemoglobin Alc, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels-the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 47 : 713-717, 2008.
 
10) Chino Y, et al : SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35 : 391-404, 2014.
PubMed
11) 安西尚彦, 大内基司 : SGLT2阻害薬を使用すると血清尿酸値が低下するのはなぜですか? (Q&A). 尿酸と血糖 1 : 150-151, 2015.
 
12) Kolz M, et al : Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5 : e1000504, 2009.
PubMed
P.439 掲載の参考文献
1) Kishimoto T : IL-6 : From its discovery to clinical applications. Int Immunol 22 (5) : 347-352, 2010.
PubMed
2) Tsutani H, et al : Interleukin 6 reduces serum urate concentrations. J Rheumatol 27 (2) : 554, 2000.
PubMed
3) 津谷寛ほか : Interleukin-6の血清尿酸値低下作用. 痛風と核酸代謝 24 (2) : 180-186, 2000.
 
4) 津谷寛ほか : サリチル酸誘導体diflunisalの血清尿酸値低下作用の機序. 尿酸 10 : 16-21, 1986.
 
5) Logan JA, et al : Serum uric acid in acute gout. Ann Rheum Dis 56 (11) : 696-697, 1997.
PubMed
6) Guerne PA, et al : Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 32 (11) : 1443-1452, 1989.
PubMed
7) Uson J, et al : Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 24 (11) : 2069-2075, 1997.
PubMed
8) Urano W, et al : The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 29 (9) : 1950-1953, 2002.
PubMed
9) Spath-Schwalbe E, et al : Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 83 (5) : 1573-1579, 1998.
 
10) Satou R, et al : IL-6 augments angiotensinogen in primary cultured renal proximal tubular cells. Mol Cell Endocrinol 311 (1-2) : 24-31, 2009.
PubMed
11) Sakurai H : Urate transporters in the genomic era. Curr Opin Nephrol Hypertens 22 (5) : 545-550, 2013.
PubMed
12) 岡田随, 鎌谷直 : 痛風と高尿酸血症に関連する遺伝子の最新知識. 痛風と核酸代謝 38 (1) : 1-12, 2014.
 
13) Mosaffa F, et al : Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res 58 (10) : 669-676, 2009.
PubMed
14) Poller B, et al : Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30 (1) : 63-70, 2010.
 
15) Englund G, et al : Efflux transporters in ulcerative colitis : decreased expression of BCRP (ABCG2) and pgp (ABCB1). Inflamm Bowel Dis 13 (3) : 291-297, 2007.
PubMed
16) Ichida K et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
P.443 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン (第2版), メディカルレビュー社, 2010.
 
2) 久保田優 : 小児科領域の高尿酸血症. 痛風と核酸代謝 33 : 37-43, 2009.
 
3) Yamanaka H : Gout and hyperuricemia in young people. Curr Opin Rheumatol 23 : 156-160, 2011.
PubMed
4) 加藤玲奈ほか : 小児期および思春期に発症した痛風に関する全国調査. 痛風と核酸代謝 38 : 43-48, 2014.
 
5) Wallace SL, et al : Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20 : 895-900, 1977.
PubMed
6) 八重樫幸典ほか : 腫瘍様の画像所見を呈した痛風の小児例. 日本整形外科学会雑誌 85 : S960, 2011.
Medical*Online
7) 押味美和子ほか : 股関節の痛風発作が初発症状であった小児白血病の一例. 栃木県整形外科医会会誌 23 : 19, 2009.
 
8) 村松友佳子ほか : ダウン症候群小児における血清尿酸値の検討. 痛風と核酸代謝 34 : 41, 2010.
 
9) 大森さゆほか : ウロモジュリン遺伝子に新規変異G210Dが同定された家族性若年性高尿酸血症性腎症の1家系. 日本小児科学会雑誌 116 : 1892-1897, 2012.
 
10) 坂崎尚徳 : チアノーゼを残したまま成人期に達した先天性心疾患症例の検討. 日本小児科学会雑誌 108 : 983-987, 2004.
 
11) Zhang W, et al : Glycogen storage disease manifested as gout and myopathy : three case reports and literature reView. Clin Rheumatol 27 : 671-674, 2008.
PubMed
12) Triick J, et al : Gout in pediatric renal transplant recipients. Pediatr Nephrol 25 : 2535-2538, 2010.
 
13) 田中栄一ほか : 痛風発症年齢の若年化に関する最近の傾向. 痛風と核酸代謝 28 : 7-11, 2004.
 
14) 作山理子 : 若年発症痛風および女性痛風の病態に関する研究. 東京女子医科大学雑誌 63 : 1463-1470, 1993.
 
15) 陳峙仰, 鎌谷直之 : 台湾における若年性痛風の臨床検討. 痛風と核酸代謝 30 : 27-32, 2006.
 
16) Mikuls TR, et al : Gout epidemiology : results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 64 : 267-272, 2005.
PubMed
17) 久保田優 : 小児・若年者に対する高尿酸血症の治療. MEDICINAL 7 : 89-96, 2012.
 
18) 鹿野高明ほか : ロタウイルス胃腸炎による高尿酸血症. 小児科臨床 62 : 1881-1885, 2009.
Medical*Online
19) Krzystek-Korpacka M, et al : Gender-spechic association of serum uric acid with metabolic syndrome and its components in juvenile obesity. Clin Chem Lab Med 49 : 129-136, 2011.
PubMed
20) 豆本公余ほか : 肥満小児のメタボリックシンドローム診断における血清尿酸値の有用性. 痛風と核酸代謝 36 : 113-120, 2012.
 
P.446 掲載の参考文献
1) Ozaki K, et al : Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32 : 650-654, 2002.
PubMed
2) Suzuki A, et al : Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34 : 395-402, 2003.
PubMed
3) Tokuhiro S, et al : An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35 : 341-348, 2003.
 
4) Klein RJ, et al : Complement factor H polymorphism in age-related macular degeneration. Science 308 : 385-389, 2005.
PubMed
5) Kamatani Y, et al : Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 42 : 210-215, 2010.
 
6) Enomoto A, et al : Molecular identhication of a renal urate anion exchanger that regulates blood urate levels. Nature 417 : 447-452, 2002.
PubMed
7) Dehghan A, et al : Association of three genetic loci with uric acid concentration and risk of gout : a genome-wide association study. Lancet 372 : 1953-1961, 2008.
 
8) Doring A, et al : SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40 : 430-436, 2008.
PubMed
9) Vitart V, et al : SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40 : 437-442, 2008.
PubMed
10) Matsuo H, et al : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83 : 744-751, 2008.
PubMed
11) Yang Q, et al : Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3 : 523-530, 2010.
PubMed
12) Tin A, et al : Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum Mol Genet 20 : 4056-4068, 2011.
 
13) Wallace C, et al : Genome-wide association study identifies genes for biomarkers of cardiovascular disease : serum urate and dyslipidemia. Am J Hum Genet 82 (1) : 139-149, 2008.
PubMed
14) Li C, et al : Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun 6 : 7041, 2015.
 
15) Endou H, Anzai N : Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 27 : 578-584, 2008.
PubMed
16) Yang J, et al : Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat Genet 47 : 1114-1120, 2015.
PubMed
17) Haseman JK Elston RC : The investigation of linkage between a quantitative trait and a marker locus. Behav Genet 2 : 3-19, 1972.
 

書評

最近チェックした商品履歴

Loading...